$46.48
+0.77 (+1.68%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NVO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 343 interventional · 157 observational · 85 with posted results
Held by 19 tracked-famous managers (Dodge & Cox, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, Markel Group Inc., MILLENNIUM MANAGEMENT LLC, +14 more) · FINRA short interest 2.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)NCT01511393observationalAnnual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market. | — | Enrolling by invitation | Other: No treatment given | Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management | 6,750 | Dec 2039 | ≤ 4,881 d | 2023-06-13 |
| A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical ParametersNCT06709040observationalNumber of adverse drug reactions | — | Enrolling by invitation | Drug: Somapacitan | Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2 | 500 | 2034-04-14 | in 2,794 d | 2026-04-06 |
| A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety InformationNCT05718570observationalNumber of Adverse drug reaction (ADRs) | — | Enrolling by invitation | Drug: Somapacitan | Adult Growth Hormone Deficiency | 400 | 2032-12-15 | in 2,309 d | 2026-06-12 |
| A Study to Evaluate Safety of Exposure to Wegovy During PregnancyNCT05872022observationalNumber of Infants with Major Congenital Malformation (MCM) | — | Enrolling by invitation | Other: No Intervention | Pregnancy, Obesity, Overweight | 728 | 2032-10-31 | in 2,264 d | 2026-01-14 |
| Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With AlhemoNCT06831734observationalNumber of adverse reaction (AR) | — | Enrolling by invitation | Drug: Concizumab | Haemophilia A, Haemophilia B | 30 | 2031-01-31 | in 1,625 d | 2026-06-15 |
| A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaNCT06609226Number of treatment emergent adverse events (TEAEs), reported for each indication and age group separatelyNon-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Etavopivat A, Etavopivat B, Etavopivat C | Sickle Cell Disease, Thalassemia | 480 | 2030-12-30 | in 1,593 d | 2026-08-13 |
| Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked HypophosphatemiaNCT07607600observationalAverage Trough Serum Phosphate Concentration | — | Not yet recruiting | Other: No treatment given | X-linked Hypophosphatemia (XLH) | 100 | 2030-07-07 | in 1,417 d | 2026-05-26 |
| Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With InhibitorsNCT06285071observationalNumber of adverse reaction (AR) | — | Enrolling by invitation | Drug: Concizumab | Haemophilia A, Haemophilia B | 23 | 2030-04-30 | in 1,349 d | 2026-06-15 |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Relative change in body mass index (BMI)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Overweight, Obesity | 460 | 2030-03-20 | in 1,308 d | 2026-07-17 |
| An Observational Study of Patients With Moderate Parkinson's DiseaseNCT05779475observationalChange in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (motor score) in OFF state | — | Enrolling by invitation | Other: No treatment given | Parkinson Disease | 96 | 2030-03-11 | in 1,299 d | 2025-12-24 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613Change in glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Diabetes Mellitus, Type 2 | 80 | 2029-09-07 | in 1,114 d | 2026-05-28 |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) deathRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo | Obesity, Heart Failure | 5,610 | 2029-07-23 | in 1,068 d | 2026-08-18 |
| Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)NCT03972345observationalNear final height (NFH) standard deviation score (SDS) measured in scores | — | Enrolling by invitation | Drug: Norditropin® FlexPro® | Growth Hormone Deficiency in Children, Born Small for Gestational Age | 750 | 2029-06-30 | in 1,045 d | 2025-09-25 |
| CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811Composite Outcome of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC6019-0001, Placebo (NNC6019-0001) | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 1,280 | 2029-06-29 | in 1,044 d | 2026-08-19 |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity | 1,150 | 2029-06-26 | in 1,041 d | 2026-07-09 |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Semaglutide, Placebo | Non-alcoholic Steatohepatitis | 1,205 | 2029-04-25 | in 979 d | 2026-08-04 |
| AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNCT07668401Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Zenagamtide, Placebo ( matched to Zenagamtide) | Obesity, Overweight | 400 | 2029-01-11 | in 875 d | 2026-07-21 |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide) | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | 2028-12-12 | in 845 d | 2026-03-12 |
| STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight LossNCT06571383Maintenance of Body Mass Index (BMI) below obesity thresholdOpen-label · Treatment | Phase 4 | Active, not recruiting | Drug: Semaglutide | Obesity | 500 | 2028-11-15 | in 818 d | 2026-06-02 |
| A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart AttackNCT07301034Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interestRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Ziltivekimab, Ziltivekimab Placebo | Myocardial Infarction | 332 | 2028-11-14 | in 817 d | 2026-03-11 |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide) | Overweight, Obesity | 650 | 2028-10-10 | in 782 d | 2026-06-25 |
| A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or PlaceboNCT07757087Change in sleeping metabolic rate (SMR)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0487-0111, Placebo · Behavioral: LED | Overweight, Obesity | 120 | 2028-09-18 | in 760 d | 2026-08-11 |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Obesity | 400 | 2028-08-28 | in 739 d | 2026-01-20 |
| A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNCT07055607observationalAbsolute change in body weight (kilograms [kg]) | — | Enrolling by invitation | Drug: Semaglutide | Obesity | 1,250 | 2028-08-15 | in 726 d | 2026-08-04 |
| A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111 ) | Obesity, Knee Osteoarthritis (OA) | 400 | 2028-08-14 | in 725 d | 2026-07-09 |
| AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Osteoarthritis, Knee | 400 | 2028-08-14 | in 725 d | 2026-08-17 |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07533175Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Diabetes Mellitus, Overweight, Obesity | 630 | 2028-08-07 | in 718 d | 2026-08-04 |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2028-07-12 | in 692 d | 2026-07-13 |
| A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ANCT05685238Arm 1 and 2: Number of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Mim8 | Haemophilia A, Haemophilia A With Inhibitors | 451 | 2028-06-30 | in 680 d | 2026-06-30 |
| AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: zenagamtide, Placebo | Overweight, Obesity | 950 | 2028-06-27 | in 677 d | 2026-07-22 |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity, Overweight, Obstructive Sleep Apnoea | 300 | 2028-06-26 | in 676 d | 2026-08-04 |
| A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMNCT07570992Number of Treatment-Emergency Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC1679-0001, Placebo | Healthy Volunteers, Diabetes Mellitus, Type 2 | 58 | 2028-06-25 | in 675 d | 2026-06-22 |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity | 600 | 2028-06-06 | in 656 d | 2026-07-09 |
| The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Obesity | 144 | 2028-05-03 | in 622 d | 2025-07-25 |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscleRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Obesity | 100 | 2028-04-28 | in 617 d | 2026-05-07 |
| A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNCT07112339Change in glycated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Insulin icodec, Basal insulin analogues | Diabetes Mellitus, Type 2 | 586 | 2028-03-23 | in 581 d | 2026-08-11 |
| French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan SyndromeNCT05308927observationalChange in height standard deviation score | — | Enrolling by invitation | Drug: Norditropin | Noonan Syndrome | 221 | 2028-03-17 | in 575 d | 2025-09-25 |
| A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesNCT07270731Number of treatment emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: NNC9733-0001, Placebo | Healthy Volunteer, Type 2 Diabetes | 60 | 2028-03-15 | in 573 d | 2026-07-20 |
| A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin AmyloidosisNCT06260709Number of Treatment Emergent Adverse EventsOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: NNC6019-0001 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 80 | 2028-02-29 | in 558 d | 2025-11-25 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Cagrisema, Semaglutide | Obesity, Type 2 Diabetes | 2,500 | 2028-02-23 | in 552 d | 2026-07-30 |
| Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNCT07770841Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Semaglutide, Placebo | Overweight, Obesity | 450 | 2028-02-22 | in 551 d | 2026-08-18 |
| A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or ObesityNCT07578584Number of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0497-0040, Placebo | Type 1 Diabetes (T1D), Overweight, Obesity, Healthy Volunteers | 146 | 2028-02-18 | in 547 d | 2026-06-04 |
| Special Use - Results Surveillance on Long-term Use With Wegovy®NCT06283667observationalNumber of Adverse Reactions (ARs) | — | Active, not recruiting | Drug: Semaglutide | Obesity | 1,071 | 2028-01-31 | in 529 d | 2026-04-22 |
| A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With ObesityNCT07508020Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0487-0111, Placebo (matched to NNC0487-0111) | Obesity | 120 | 2028-01-19 | in 517 d | 2026-04-27 |
| Cities for Better Health Childhood Obesity Prevention InitiativeNCT06855563Body mass index z-score (BMI-z) adjusted for age and sexNon-randomized · Open-label · Prevention | Not applicable | Enrolling by invitation | Behavioral: Community-based intervention packages | Obesity | 36,000 | 2027-12-31 | in 498 d | 2025-12-19 |
| A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYNNCT03745924observationalNumber of Adverse Drug Reactions (ADRs) (FIX inhibitors, allergic reactions, and thromboembolic events) | — | Enrolling by invitation | Drug: Nonacog beta pegol | Haemophilia B | 60 | 2027-12-15 | in 482 d | 2026-06-12 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionNCT07587710AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: NNC0487-0111 | Overweight, Obesity | 35 | 2027-12-01 | in 468 d | 2026-05-14 |
| A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNCT07632404observationalChange in glycated haemoglobin (HbA1c) | — | Not yet recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 214 | 2027-12-01 | in 468 d | 2026-06-08 |
| Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNCT07658417observationalChange in glycated haemoglobin (HbA1c) | — | Not yet recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 216 | 2027-12-01 | in 468 d | 2026-06-22 |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placeboRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Cagrilintide, Placebo (matched to Cagrilintide) | Obesity, Overweight | 114 | 2027-11-19 | in 456 d | 2026-06-25 |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyNCT06979362Main phase: Change in normalised microRNA-132-3p (miR-132)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: CDR132L, Placebo | Heart Failure | 200 | 2027-11-16 | in 453 d | 2026-08-05 |
| Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesNCT07535307Change in M-value in Hyperinsulinaemic euglycaemic clamp (HEC)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0487-0111, Placebo | Diabetes Mellitus | 80 | 2027-11-11 | in 448 d | 2026-04-24 |
| A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 1,500 | 2027-11-07 | in 444 d | 2026-08-04 |
| WEgovy Real World Assessment of Weight Loss in KoreaNCT07280221observationalPercentage change in body weight | — | Enrolling by invitation | Drug: Semaglutide | Obesity | 500 | 2027-10-31 | in 437 d | 2025-12-12 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086Change in sleeping metabolic rate (SMR)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CagriSema (Cagrilintide B + semaglutide I) · Behavioral: Low Energy Diet | Obesity | 80 | 2027-10-12 | in 418 d | 2025-10-08 |
| A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityNCT06577766Part A: Number of treatment emergent adverse events (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: NNC0638-0355, Placebo (NNC0638-0355) | Obesity, Overweight | 63 | 2027-10-11 | in 417 d | 2026-08-17 |
| Multiple Dose Study for a New Medication to Potentially Treat Liver DiseasesNCT06891365Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0581-0001, Placebo (NNC0581-0001) | Healthy Volunteers, Hepatic Steatosis | 48 | 2027-10-11 | in 417 d | 2026-04-07 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388UBT251: Change in glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: UBT251, UBT251 Placebo, Semaglutide, Semaglutide Placebo | Diabetes Mellitus, Type 2 | 300 | 2027-10-04 | in 410 d | 2026-08-10 |
| Adverse Event Data Collection From External Registries on Nonacog Beta PegolNCT03690336observationalAdverse Drug Reactions (ADRs) reported to the registries with suspected relation to nonacog beta pegol in patients with haemophilia B | — | Enrolling by invitation | Drug: Nonacog beta pegol | Haemophilia B | 10 | 2027-10-01 | in 407 d | 2025-06-02 |
| A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityNCT07767175Part A: Number of treatment emergent adverse events (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Not yet recruiting | Drug: NNC0721-8060, Semaglutide, Placebo | Overweight, Obesity | 142 | 2027-09-23 | in 399 d | 2026-08-17 |
| Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108NCT07153172Number of adverse eventsOpen-label · Other | Phase 1 | Recruiting | Drug: INV-347 | Obesity | 91 | 2027-09-15 | in 391 d | 2026-03-06 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954Change in glycated haemoglobin (HbA1c) (week 16)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: NNC0662-0419, Semaglutide, Placebo | Diabetes Mellitus, Type 2 | 270 | 2027-09-03 | in 379 d | 2026-08-10 |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal strokeRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Semaglutide, Placebo | Cardiovascular Disease | 7,101 | 2027-09-01 | in 377 d | 2026-07-17 |
| A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseNCT06612268Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contactRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Etavopivat, Placebo | Sickle Cell Disease | 408 | 2027-08-27 | in 372 d | 2026-08-13 |
| A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaNCT07157423Number of thromboembolic eventsNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Eptacog alfa (NovoSeven) | Severe Postpartum Haemorrhage | 64 | 2027-08-26 | in 371 d | 2026-08-13 |
| A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyNCT05503927observationalNumber of Infants with Major Congenital Malformation (MCM) | — | Enrolling by invitation | Other: No Intervention | Pregnancy, Obesity, Overweight | 2,701 | 2027-08-15 | in 360 d | 2026-07-21 |
| A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With ObesityNCT07693868Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC6022-0004, Placebo | Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP) | 128 | 2027-08-01 | in 346 d | 2026-08-19 |
| General Use-results Surveillance With Awiqli in Patients With Diabetes MellitusNCT06807190observationalNumber of Adverse Reactions (ARs) | — | Recruiting | Drug: Insulin Icodec | Diabetes Mellitus, Type 1 | 630 | 2027-07-31 | in 345 d | 2026-06-29 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021Number of gastrointestinal adverse eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo | Obesity | 230 | 2027-07-12 | in 326 d | 2026-07-10 |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF VisitRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ziltivekimab, Placebo | Heart Failure | 4,899 | 2027-07-02 | in 316 d | 2026-08-12 |
| A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®NCT04574076observationalNumber of Adverse Events (AEs) reported during the study period | — | Enrolling by invitation | Drug: Turoctocog alfa pegol (N8-GP) | Haemophilia A | 60 | 2027-06-03 | in 287 d | 2025-12-22 |
| A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.NCT07448623Mean Standard Uptake Value Ratio (SUVRmean) in myocardiumNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Coramitug | Transthyretin Amyloid Cardiomyopathy | 14 | 2027-05-30 | in 283 d | 2026-04-13 |
| A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c.Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Cagrilintide D, Cagrilintide B and placebo semaglutide I | Obesity, Overweight | 234 | 2027-05-28 | in 281 d | 2026-06-26 |
| A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Cagrilintide, Placebo cagrilintide, Placebo semaglutide | Overweight, Obesity | 285 | 2027-05-18 | in 271 d | 2026-08-04 |
| A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyNCT06979375Main Phase: Change in normalised microRNA-132-3p (miR-132)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: CDR132L, Placebo | Heart Failure | 200 | 2027-05-16 | in 269 d | 2026-03-11 |
| A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver FatNCT07214870Number of Treatment-emergent adverse event (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC4005-001, Placebo | Fatty Liver Disease | 60 | 2027-05-14 | in 267 d | 2026-02-11 |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Placebo (matched to Cagrilintide) | Overweight, Obesity, Type 2 Diabetes | 330 | 2027-05-12 | in 265 d | 2026-08-03 |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Placebo | Obesity, Overweight | 300 | 2027-05-11 | in 264 d | 2026-08-06 |
| A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become PregnantNCT07710729AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady stateNon-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: UBT251, Oral contraceptive, Acetaminophen | Overweight, Obesity | 40 | 2027-04-27 | in 250 d | 2026-07-17 |
| A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack boxRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Cagrilintide, Placebo Cagrilintide | Overweight, Obesity | 120 | 2027-04-13 | in 236 d | 2026-05-15 |
| A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body WeightNCT07525791Area under curve (AUC) 0-24 h, EE, steady state (SS): The area under the EE plasma concentration-time curve (pre-dose to 24 hours post-dose)Open-label · Treatment | Phase 1 | Recruiting | Drug: NNC0662-0419, Oral contraceptive, Acetaminophen | Overweight, Obesity | 45 | 2027-04-08 | in 231 d | 2026-04-24 |
| A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNCT07710768AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single doseNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: UBT251, Cocktail (Warfarin/Caffeine/Midazolam) | Obesity, Overweight | 44 | 2027-04-07 | in 230 d | 2026-08-18 |
| A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) ParticipantsNCT07532863observationalCardiometabolic profile: Systolic blood pressure at baseline | — | Recruiting | Other: No treatment given | Diabetes Mellitus, Type 2 | 400 | 2027-03-27 | in 219 d | 2026-07-28 |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Obesity | 609 | 2027-03-01 | in 193 d | 2026-07-24 |
| A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in KoreaNCT07018544observationalNumber (incidence) of AEs | — | Enrolling by invitation | Other: semaglutide | Obesity and Overweight | 840 | 2027-02-28 | in 192 d | 2025-06-12 |
| Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese PhysiciansNCT07682363observationalTo investigate attitudes and perceptions concerning the reasons for further severity assessment (mainly refers to the assessment of liver fibrosis) following a MASLD diagnosis | — | Recruiting | Other: No treatment is given | Liver Disease | 470 | 2027-02-23 | in 187 d | 2026-07-02 |
| A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANCT07220564Number of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: NNC0442-0344 A | Haemophilia A | 30 | 2027-02-05 | in 169 d | 2026-08-10 |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoeaRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP | Overweight, Obese | 100 | 2027-01-26 | in 159 d | 2026-04-13 |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199Change in glycosylated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Insulin icodec, Insulin glargine, Insulin aspart | Diabetes Mellitus, Type 1 | 877 | 2027-01-25 | in 158 d | 2026-06-29 |
| A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNCT07437079Number of treatment emergent adverse events (TEAE) - Part ARandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC6989-0001, Placebo (NNC6989-0001) | Overweight, Obesity | 132 | 2027-01-21 | in 154 d | 2026-07-29 |
| A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNCT07160816observationalChange in glycated haemoglobin (HbA1c) | — | Active, not recruiting | Drug: Insulin icodec | Diabetes Mellitus, Type 1 | 245 | 2027-01-20 | in 153 d | 2026-06-29 |
| A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNCT07218627Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0537-1482, Placebo | Heart Failure | 36 | 2027-01-15 | in 148 d | 2026-08-18 |
| A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityNCT07395687Part A - Number of treatment emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: UBT251, Placebo | Overweight, Obesity | 333 | 2027-01-14 | in 147 d | 2026-04-21 |
| Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®NCT05230550observationalNumber of adverse events | — | Active, not recruiting | Drug: Somapacitan | Adult Growth Hormone Deficiency | 200 | 2026-12-31 | in 133 d | 2026-04-13 |
| A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsNCT07656454Area under the CDR132L plasma concentration-time curve (AUC 0-tz) from 0 hours to tz after a single dose, where tz is the time of last quantifiable concentrationRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CDR132L (i.v.), CDR132L (s.c.) | Healthy Volunteers, Heart Failure | 32 | 2026-12-31 | in 133 d | 2026-06-30 |
| Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNCT07713901observationalTime to first occurence of Medullary Thyroid Carcinoma (MTC) | — | Enrolling by invitation | Other: No treatment given | Medullary Thyroid Carcinoma | 93,600,000 | 2026-12-31 | in 133 d | 2026-08-04 |
| A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNCT07566390Number of treatment emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0113-5840, Placebo | Obesity, Overweight | 48 | 2026-12-26 | in 128 d | 2026-08-04 |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNCT06118281Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal strokeRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Ziltivekimab, Placebo | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | 10,000 | 2026-12-14 | in 116 d | 2026-04-14 |
| A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNCT07184632Part A: Number of treatment-emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: NNC0662-0419, Placebo | Overweight, Obesity | 224 | 2026-12-14 | in 116 d | 2026-05-07 |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Liraglutide, Oral Semaglutide, Semaglutide | Obesity | 71 | 2026-12-13 | in 115 d | 2026-07-21 |
| Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNCT07769489Injection pain rated on a Visual Analogue Scale (VAS)Randomized · Triple-masked · Other | Phase 1 | Not yet recruiting | Device: Syringe Pump | Healthy Participants | 100 | 2026-12-09 | in 111 d | 2026-08-18 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05689372observationalNumber (incidence) of adverse events (AEs) | — | Enrolling by invitation | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 600 | 2026-11-30 | in 102 d | 2026-05-05 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05714683observationalNumber (Incidence) of adverse events (AEs) | — | Not yet recruiting | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 600 | 2026-10-30 | in 71 d | 2025-12-05 |
| Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNCT07653139observationalChoice of treatment alternative in discrete choice tasks | — | Not yet recruiting | Other: No treatment given | Haemophilia A | 150 | 2026-10-26 | in 67 d | 2026-06-17 |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ziltivekimab, Placebo | Heart Failure, Systemic Inflammation | 680 | 2026-10-01 | in 42 d | 2026-07-31 |
| Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.NCT07154238observationalDescription of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management | — | Enrolling by invitation | Other: No treatment given | Obesity | 2,546 | 2026-09-30 | in 41 d | 2025-11-25 |
| Korean Real-world Study on MASLD/MASH Outcomes.NCT07739901observationalOccurrence of decompensated cirrhosis | — | Active, not recruiting | Other: No treatment is given | MASLD/MASH | 10,000 | 2026-09-30 | in 41 d | 2026-07-31 |
| A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesNCT07087795Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Randomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: NNC0194-0499, Placebo, Semaglutide | Diabetes Mellitus, Type 1 | 96 | 2026-09-12 | in 23 d | 2026-08-13 |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintideRandomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Cagrilintide B, Cagrilintide D | Overweight, Obesity | 50 | 2026-09-03 | in 14 d | 2026-08-17 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698Change in urinary albumin-to-creatinine ratio (UACR) at week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: NNC0519-0130, Placebo, Semaglutide | Chronic Kidney Disease | 465 | 2026-09-01 | in 12 d | 2026-03-11 |
| A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaNCT07456774observationalTime to 3P major adverse cardiovascular events | — | Enrolling by invitation | — | Type 2 Diabetes | 100,000 | 2026-08-31 | in 11 d | 2026-05-20 |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy | 142 | 2026-08-21 | in 1 d | 2025-12-05 |
| Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based StudyNCT07673822observationalProportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)) | — | Enrolling by invitation | Other: No treatment given | Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk | 800,000 | 2026-08-03 | — | 2026-06-29 |
| Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not ClosedNCT06109935observationalNumber of adverse reactions (AR) | — | Enrolling by invitation | Drug: Somapacitan | Growth Hormone Deficiency in Children | 200 | 2026-07-31 | — | 2026-04-29 |
| An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine EsperoctNCT05621746observationalChange in haemophilia joint health score (HJHS) | — | Recruiting | Drug: Esperoct | Haemophilia A | 100 | 2026-06-30 | — | 2025-06-02 |
| A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic HyperuricemiaNCT06859073Number of Treatment-emergent adverse event (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: NNC4004-0002, Placebo | Healthy Volunteers, Hyperuricemia | 60 | 2026-06-01 | — | 2025-09-24 |
| Weight Loss in Adults Using Semaglutide (Real-world Study)NCT07627074observationalChange in body weight | — | Recruiting | Drug: Semaglutide | Overweight, Obesity | 35,000 | 2026-06-01 | — | 2026-06-04 |
| A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without InhibitorsNCT05135559For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodesNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Concizumab | Haemophilia A and B With and Without Inhibitors | 153 | 2026-04-21actual | — | 2026-08-13 |
| A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A) | Obesity, Overweight | 177 | 2026-03-26 | — | 2025-05-25 |
| Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNCT04682145observationalAdverse events (AEs) reported to the registry with suspected relation to turoctocog alfa pegol, Adverse Drug Reactions (ADRs), in patients with haemophilia A for renal, hepatic and neurological events. | — | Enrolling by invitation | Drug: Turoctocog alfa pegol | Haemophilia A | 50 | 2026-02-01 | — | 2025-09-25 |
| Defeat Rare Disease in Asia and Pacific (APAC) DRDA - HaemophiliaNCT07163260observationalEstimated prevalence of haemophilia | — | Enrolling by invitation | Other: No treatment given | Haemophilia | 244 | 2025-12-19 | — | 2025-10-24 |
| A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNCT05726227Group Kids: Change in body mass index (BMI)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Semaglutide, Placebo | Obesity | 210 | 2025-10-15actual | — | 2026-08-07 |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796CagriSema versus placebo: Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Obesity | 3,400 | 2024-10-30actual | — | 2026-07-17 |
| A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to GrowNCT05330325Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Somapacitan, Norditropin® | SGA, Turner Syndrome, Noonan Syndrome, ISS | 412 | 2024-08-05actual | — | 2026-06-12 |
| A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9NCT05723835results2025-11-21Number of Adverse Events (AEs) Reported in Children Born Small for Gestational Age- Weeks 0 to 26Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Somapacitan | SGA, Turner Syndrome, Noonan Syndrome, ISS | 47 | 2024-06-07actual | — | 2026-08-13 |
| SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082Relative change in BMI (Body mass index)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Liraglutide, Placebo | Obesity | 78 | 2023-08-01actual | — | 2026-07-09 |
| Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without InhibitorsNCT04082429results2025-10-31Haemophilia A Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding EpisodesRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Concizumab | Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors | 156 | 2022-07-12actual | — | 2026-08-13 |
| Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With InhibitorsNCT04083781results2025-04-27Rate of Treated Spontaneous and Traumatic Bleeding EpisodesRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Concizumab | Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | 134 | 2021-12-27actual | — | 2026-06-12 |
| A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayNCT03878446results2024-06-20Height VelocityRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Somapacitan, Norditropin® | Short Stature Children Born Small for Gestational Age (SGA) | 62 | 2021-05-05actual | — | 2026-08-13 |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: The study is withdrawn due to strategic reasons. | Drug: Cagrisema, Placebo CagriSema | Overweight, Obesity | 0 | 2027-11-29 | in 466 d | 2026-07-09 |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740Change in glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The study is withdrawn due to strategic reasons. | Drug: CagriSema, Placebo CagriSema | Diabetes Mellitus, Type 2 | 0 | 2027-08-25 | in 370 d | 2026-07-09 |
| A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesNCT07271251Change in glycated haemoglobin (HbA1c).Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Oral semaglutide | Type 2 Diabetes | 267 | 2026-06-29actual | — | 2026-08-13 |
| ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationNCT05021835Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal strokeRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C) | Cardiovascular Risk, Chronic Kidney Disease, Inflammation | 6,385 | 2026-06-09actual | — | 2026-07-28 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Tirzepatide | Diabetes Mellitus, Type 2 | 1,023 | 2026-06-02actual | — | 2026-07-17 |
| A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy PeopleNCT07238816AUC0-∞: the area under the plasma Inno8 concentration-time curve from time 0 to infinity after a single oral doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0442-0344 A | Haemophilia A | 80 | 2026-05-08actual | — | 2026-06-17 |
| SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in HungaryNCT06269120observationalGlycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5% | — | Completed | Drug: Oral Semaglutide | Type 2 Diabetes | 243 | 2026-05-05actual | — | 2026-08-13 |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Obesity | 300 | 2026-04-22actual | — | 2026-05-05 |
| A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 DiabetesNCT07305805AUC, GIR,SS: Area under the glucose infusion rate-time curve at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0363-1063 | Diabetes Mellitus, Type 1 | 36 | 2026-04-21actual | — | 2026-06-05 |
| A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management ProgramNCT06805539observationalCompletion of the electronic informed consent process (e-consent) | — | Completed | Other: No treatment given | Overweight, Obesity | 146 | 2026-04-20actual | — | 2026-05-04 |
| A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy MenNCT06649630SAD: Number of treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0442-0344 A, Placebo | Haemophilia A | 95 | 2026-03-26actual | — | 2026-04-01 |
| Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseNCT05725902Effect of etavopivat on cerebral blood flow (CBF)Open-label · Treatment | Phase 2 | Completed | Drug: Etavopivat | Sickle Cell Disease | 12 | 2026-03-09actual | — | 2026-04-08 |
| A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 DiabetesNCT06685185Part 1 SAD: Number of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0363-1063, Placebo, Insulin degludec, Insulin detemir | Diabetes Mellitus, Type 1 | 117 | 2026-03-08actual | — | 2026-04-09 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969Change in glycated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Tirzepatide | Type 2 Diabetes | 1,024 | 2026-03-04actual | — | 2026-04-22 |
| A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin PumpNCT07068295AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hourRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0471-0119 H, Insulin Aspart | Diabetes Mellitus, Type 2 | 65 | 2026-02-22actual | — | 2026-04-07 |
| A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body WeightNCT07004322AUC, NNC0519-0130, SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment periodRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0519-0130, Placebo | Diabetes Mellitus, Type 2, Obesity | 20 | 2026-01-28actual | — | 2026-03-31 |
| A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk PopulationNCT07201831observationalDescription of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors | — | Completed | Other: No treatment given | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 1,330 | 2026-01-17actual | — | 2026-03-12 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityNCT06718998Number of Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0519-0130 | Obesity | 134 | 2026-01-12actual | — | 2026-04-03 |
| User Experience With DuraTouch® in Patients With Type 1 or Type 2 DiabetesNCT07052292observationalParticipant rating the ease of use, convenience and satisfaction with the device | — | Completed | Device: DuraTouch® | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 128 | 2026-01-09actual | — | 2026-04-09 |
| Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide, Cagrilintide, Placebo semaglutide, Placebo cagrilintide | Diabetes Mellitus, Type 2 | 158 | 2025-12-28actual | — | 2026-02-27 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.NCT07121153Number of treatment emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: NNC0487-0111 A, Placebo A | Overweight, Obesity | 36 | 2025-12-20actual | — | 2026-02-17 |
| A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real WorldNCT07141914observationalRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | — | Completed | Other: No treatment given, No treatment given | Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention | 285,327 | 2025-12-19actual | — | 2026-01-23 |
| A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).NCT07081178observationalChange in relative body weight | — | Terminatedsponsor's stated reason: The study was cancelled prematurely due to lack of patients. | Drug: Semaglutide | Obesity | 100 | 2025-12-18actual | — | 2026-04-27 |
| Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE）NCT07358052observationalPrimary End point | — | Completed | Other: No treatment given | Obesity, Overweight | 551,931 | 2025-12-12actual | — | 2026-01-22 |
| A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 DiabetesNCT06567041Number of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0519-0130, Placebo | Diabetes Mellitus, Type 2, Obesity | 82 | 2025-12-10actual | — | 2025-12-31 |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weightRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Tirzepatide | Obesity | 809 | 2025-12-08actual | — | 2026-02-06 |
| Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry DataNCT04572165observationalOccurrence of first time malignant neoplasm of pancreas | — | Completed | Drug: Ozempic®, Active Comparator, Rybelsus® | Diabetes Mellitus, Type 2 | 194,928 | 2025-11-25actual | — | 2026-06-11 |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130Change in Enhanced Liver Fibrosis (ELF)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B) | Alcohol-related Liver Disease | 270 | 2025-11-21actual | — | 2026-03-12 |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Type 2 Diabetes Mellitus | 2,734 | 2025-11-19actual | — | 2026-07-08 |
| Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A PatientsNCT06574984observationalAnnual bleeding Rate (ABRs) among patients treated with different regimen of turoctocog alfa after previous FVIII replacement therapy | — | Completed | Drug: Turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 329 | 2025-11-04actual | — | 2026-06-17 |
| A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy PeopleNCT07029568PART A: Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0705-0001, Placebo | Healthy Volunteers, Chronic Kidney Disease | 116 | 2025-11-04actual | — | 2026-03-11 |
| A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or ObesityNCT07101783AUC; The area under the NNC0662-0419 plasma concentration-time curveRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0662-0419 | Overweight, Obesity | 100 | 2025-10-31actual | — | 2025-12-23 |
| Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure ManagementNCT07160829observationalPerceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease | 608 | 2025-10-30actual | — | 2026-02-11 |
| A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy AdultsNCT05624580Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0582-0001, Placebo | Healthy Volunteers | 56 | 2025-10-16actual | — | 2025-12-24 |
| Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and VietnamNCT06843473observationalProportion of Weight-Related Complications Across Different Body Mass Index (BMI) Classes | — | Completed | Other: No treatment given | Obesity, Obesity-related Complications | 1,170 | 2025-10-11actual | — | 2026-04-08 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174Change in glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Type 2 Diabetes | 189 | 2025-10-01actual | — | 2026-04-02 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874Change in HbA1cRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral) | Type 2 Diabetes (T2D) | 448 | 2025-10-01actual | — | 2026-08-13 |
| Post-marketing Surveillance (Use Result Surveillance) With Refixia®NCT03875547observationalNumber of Adverse Reactions (ARs) | — | Completed | Drug: Refixia® | Haemophilia B | 28 | 2025-09-30actual | — | 2026-04-24 |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372Change in urinary albumin-to-creatinine ratio (UACR)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Chronic Kidney Disease, Type 2 Diabetes, Obesity | 626 | 2025-09-24actual | — | 2026-04-01 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047Change in Glycated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0519-0130, Placebo, Trizepatide | Diabetes Mellitus, Type 2 | 299 | 2025-09-19actual | — | 2026-08-13 |
| A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Semagludtide, Placebo (semaglutide) | Early Alzheimer's Disease | 1,840 | 2025-09-16actual | — | 2026-07-07 |
| A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Early Alzheimer´s Disease | 1,840 | 2025-09-15actual | — | 2026-06-26 |
| A Study on the Effect of Etavopivat on Heart Rhythm in Healthy ParticipantsNCT07023029Part A: Number of treatment-emergent adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Etavopivat, Moxifloxacin, Placebo | Healthy Volunteers, Sickle Cell Disease, Thalassemia | 33 | 2025-09-12actual | — | 2026-01-02 |
| A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After MenopauseNCT06513104Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady stateOpen-label · Treatment | Phase 1 | Completed | Drug: NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol | Diabetes Mellitus, Type 2 | 47 | 2025-09-10actual | — | 2026-03-12 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161Change in Glycated Haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Type 2 Diabetes | 274 | 2025-09-09actual | — | 2025-11-28 |
| First Human Dose Trial for a New Medication to Potentially Treat Liver DiseasesNCT05599945Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0581-0001, Placebo (NNC0581-0001) | Healthy Volunteers, Hepatic Steatosis | 48 | 2025-08-29actual | — | 2025-10-09 |
| Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney DiseaseNCT06655493observationalHigh Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L | — | Completed | Other: No treatment given | Systemic Inflammation (hsCRP) | 756 | 2025-08-28actual | — | 2025-10-21 |
| SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes TrialNCT04972721observationalTime to all-cause death | — | Completed | Other: No treatment given | Overweight, Obesity | 3,439 | 2025-08-25actual | — | 2026-02-11 |
| A Research Study on Etavopivat in Participants With and Without Liver DiseaseNCT06336018Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etavopivat | Liver Diseases | 48 | 2025-08-01actual | — | 2026-06-18 |
| A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or ObesityNCT06737536Part A: Number of treatment emergent adverse events (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: NNC0662-0419 · Other: Placebo (NNC0662-0419) | Overweight, Obesity | 100 | 2025-07-26actual | — | 2025-09-19 |
| Research Study Investigating How Well NDec Works in People With Sickle Cell DiseaseNCT05405114Change in total haemoglobinRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo | Sickle Cell Disease | 96 | 2025-07-24actual | — | 2026-07-22 |
| Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsNCT06588504Adults cohort: Time to plasma glucose (PG) recovery, where PG recovery is defined as the first increase in PG of greater than or equal to (>=) 20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baselineRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Dasiglucagon, Glucagon | Diabetes Mellitus, Type 1 | 38 | 2025-07-20actual | — | 2025-12-05 |
| A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin PumpNCT06809621AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hourRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0471-0119 H, Insulin aspart | Diabetes Mellitus, Type 1 | 43 | 2025-07-16actual | — | 2025-09-02 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IVNCT06642584Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curveRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide B, Semaglutide J, Semaglutide L, Semaglutide M, Semaglutide N | Healthy Volunteers Type 2 Diabetes | 90 | 2025-07-10actual | — | 2025-10-20 |
| CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in IndiaNCT07121114observationalProportion of individuals with established Cardio Vascular Disease (CVD) | — | Completed | Other: No treatment given | Type 2 Diabetes Mellitus | 1,500 | 2025-07-09actual | — | 2025-08-13 |
| A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)NCT05035082results2026-08-10Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: semaglutide, oral glucose-lowering medications (commercially available) | Diabetes Mellitus, Type 2 | 1,018 | 2025-06-18actual | — | 2026-08-10 |
| A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityNCT06478563Phase A: The area under the NNC0487-0111 plasma concentration-time curve during a dosing interval at steady stateRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: NNC0487-0111 (formulation D), NNC0487-0111 (formulation C) | Obesity, Overweight | 133 | 2025-06-05actual | — | 2025-08-11 |
| A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)NCT06269107Change in glycated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: IcoSema, Insulin glargine | Type 2 Diabetes | 485 | 2025-05-27actual | — | 2026-06-05 |
| A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up DatabaseNCT06741111observationalThe proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway. | — | Completed | Other: No treatment given | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH) | 1,233,970 | 2025-05-27actual | — | 2025-06-22 |
| A Research Study of the Effect of Etavopivat on Other Drugs in Healthy ParticipantsNCT06813924Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady stateNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin | Healthy Volunteers Sickle Cell Disease, Thalassemia | 37 | 2025-05-27actual | — | 2025-09-25 |
| A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the MedicineNCT06642571AUC,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve during a dosing interval at steady state (SS)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0519-0130 B, NNC0519-0130 C | Obesity | 46 | 2025-05-17actual | — | 2025-11-25 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingNCT06820476Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0487-0111, Placebo (NNC0487-0111) | Overweight, Obesity | 29 | 2025-05-14actual | — | 2025-08-20 |
| Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®NCT04469855observationalNumber of adverse events (AEs) | — | Completed | Drug: semaglutide | Diabetes Mellitus, Type 2 | 3,217 | 2025-05-12actual | — | 2026-05-19 |
| A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesNCT06340854results2026-07-02Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin icodec, Insulin glargine | Diabetes, Type 2 | 412 | 2025-05-08actual | — | 2026-08-11 |
| A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the SkinNCT06625307Number of treatment emergent adverse events (TEAE) in cohorts 1 and 2Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0537-1482, Placebo | Healthy Volunteers, Heart Failure | 31 | 2025-05-04actual | — | 2026-06-22 |
| Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961observationalHigh sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no) | — | Completed | Other: No treatment given | Cardiovascular Risk, Heart Failure, Chronic Kidney Disease | 18,198 | 2025-04-30actual | — | 2025-05-09 |
| A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 DiabetesNCT04596631Change from baseline in glycosylated haemoglobin (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Oral semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 132 | 2025-04-29actual | — | 2026-03-11 |
| Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese ParticipantsNCT06069895Number of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0113-6856, Placebo | Healthy Participants | 170 | 2025-04-23actual | — | 2025-06-18 |
| A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This TreatmentNCT06478550observationalPersistency of semaglutide s.c. treatment in PSS app with connectivity vs control arm (Yes/No) (HCP reported) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 304 | 2025-04-23actual | — | 2026-02-11 |
| A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 DiabetesNCT05813912results2026-06-03Change in Glycated Haemoglobin (HbA1c)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin Icodec, Semaglutide | Diabetes Mellitus, Type 2 | 148 | 2025-04-14actual | — | 2026-06-03 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightNCT06326060Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0519-0130, Placebo, Tirzepatide | Obesity | 354 | 2025-04-10actual | — | 2026-04-15 |
| A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092Change in mean postprandial appetite score based on visual analogue scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Other: No treatment given · Drug: Cagrilintide and Semaglutide, Placebo | Overweight, Obesity | 164 | 2025-04-07actual | — | 2026-01-08 |
| A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight RangeNCT06041217results2026-05-18Change in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo | Overweight, Obesity | 242 | 2025-04-02actual | — | 2026-05-18 |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307AUC0-∞,cagri,0.25 milligram (mg)/0.25mg,SD: Area under the cagrilintide concentration-time curve after a single dose 0.25 mg/0.25 mg CagriSema A in PDS290 pen-injector or CagriSema in DV3384 pen-injectorRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: CagriSema (cagrilintide B and semaglutide I), CagriSema A | Obesity | 18 | 2025-03-28actual | — | 2025-08-27 |
| Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real WorldNCT06874751observationalRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | — | Completed | Other: No treatment given, No treatment given | Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD) | 45,456 | 2025-03-28actual | — | 2025-05-21 |
| A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar LevelNCT06153537observationalChange in glycated haemoglobin (HbA1c) | — | Completed | Drug: Insulin degludec | Diabetes Mellitus, Type 2 | 179 | 2025-03-24actual | — | 2026-01-09 |
| A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short StatureNCT05894876observationalThe frequency of genetic variants that significantly differ between the two responder groups | — | Terminatedsponsor's stated reason: Due to recruitment challenges, the sponsor has decided to terminate the study prematurely. | Other: No treatment is given | Idiopathic Short Stature | 43 | 2025-03-21actual | — | 2025-12-12 |
| A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become PregnantNCT06461039The area under the ethinylestradiol plasma concentration time curve at steady stateOpen-label · Treatment | Phase 1 | Completed | Drug: NNC0487-0111 A, NNC0487-0111 C, Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC), Acetaminophen - 500 mg/15 ml | Obesity | 43 | 2025-03-16actual | — | 2025-05-08 |
| A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the BloodNCT05979428Part A (SAD): Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0491-6075, Placebo | Healthy Volunteers, Dyslipidaemia | 106 | 2025-03-14actual | — | 2025-05-04 |
| A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged FastingNCT06288412Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec, Insulin degludec | Diabetes Mellitus, Type 2 | 30 | 2025-03-10actual | — | 2026-06-08 |
| A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535results2026-05-11Change in Glycated Haemoglobin (HbA1c) [Noninferiority]Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated) | Diabetes Mellitus, Type 2, Obesity | 573 | 2025-03-05actual | — | 2026-05-11 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionNCT06559527AUC0111,0-∞,SD: Area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0487-0111 | Diabetes Mellitus, Type 2, Obesity, Overweight | 42 | 2025-02-24actual | — | 2025-03-30 |
| A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 DiabetesNCT06113341observationalParticipant downloaded and actively used the app (Yes/No) | — | Withdrawnsponsor's stated reason: The study has been cancelled due to the study's rejection from the local Italian ethics Committee | Drug: IDegLira | Diabetes Mellitus, Type 2 | 0 | 2025-02-23 | — | 2024-10-01 |
| A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) AmyloidosisNCT05442047Change in 6-minute walk test (6-MWT)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC6019-0001, Placebo (NNC6019-0001) | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | 105 | 2025-02-17actual | — | 2026-02-17 |
| A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy PeopleNCT06336005Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC6022-0001, Placebo (NNC6022-0001) | Healthy Volunteers, Cardiometabolic Diseases | 56 | 2025-02-10actual | — | 2026-06-30 |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519Relative change in body weightRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Overweight, Obesity, Type 2 Diabetes Mellitus | 1,200 | 2025-01-28actual | — | 2026-01-28 |
| Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesNCT06083675Change in glycated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Due to internal reprioritization, trial was cancelled. | Drug: Semaglutide, Empagliflozin, Metformin | Diabetes Mellitus, Type 2 | 0 | 2025-01-24 | — | 2024-02-26 |
| A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925Relative Change in Body WeightRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo Semaglutide | Obesity or Overweight | 331 | 2025-01-17actual | — | 2026-01-22 |
| Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)NCT05890976Relative Change in Body WeightRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Semaglutide, Semaglutide Placebo | Overweight, Obesity | 200 | 2025-01-16actual | — | 2026-01-22 |
| Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641observationalIncidence of adverse events (AEs) by preferred term (PT) | — | Completed | Drug: Liraglutide | Obesity | 300 | 2025-01-13actual | — | 2026-01-09 |
| Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different TreatmentsNCT04809311observationalParticipant invited to consent and consented via e-signature (Yes/No) | — | Completed | Drug: Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1) | Diabetes Mellitus, Type 2 | 156 | 2025-01-07actual | — | 2025-03-21 |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weightRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Cagrilintide, Semaglutide, Placebo Semaglutide, Placebo Cagrilintide | Obesity or Overweight | 300 | 2025-01-06actual | — | 2026-01-09 |
| SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world DataNCT06769646observationalPrevalence of various CKD stages among patients with type 2 diabetes in the THIN database | — | Completed | Other: No tretament given | Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) | 110,074 | 2025-01-06actual | — | 2025-03-27 |
| A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.NCT06188026(AUC0-24h,EE,SS), area under the ethinylestradiol plasma concentration-time curve during a dosing interval at steady stateOpen-label · Treatment | Phase 1 | Completed | Drug: NNC0194-0499, ethinylestradiol/levonorgestrel | Healthy Volunteers (Non-alcoholic Steatohepatitis) | 34 | 2024-12-30actual | — | 2025-02-18 |
| Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 DiabetesNCT06507475observationalChange in Glycated Haemoglobin (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 209 | 2024-12-20actual | — | 2025-12-30 |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882Improvement in liver fibrosis and no worsening of NASH (Yes/No)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo | Non-alcoholic Steatohepatitis | 698 | 2024-12-17actual | — | 2025-11-19 |
| A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver FunctionNCT05917938AUC0-∞, Single Dose, NNC0194-0499: the area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0194-0499 | Hepatic Impairment, Healthy Volunteers | 33 | 2024-12-16actual | — | 2026-02-11 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT04952779observationalIncidence of Adverse Events (AEs) by preferred term | — | Completed | Drug: Xultophy® (insulin degludec/liraglutide) | Diabetes Mellitus, Type 2 | 750 | 2024-12-15actual | — | 2025-12-31 |
| A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and NephrologistsNCT06589791observationalHealth care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 1,500 | 2024-12-05actual | — | 2025-12-05 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249results2026-01-14Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide | Obesity | 500 | 2024-11-27actual | — | 2026-01-14 |
| A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinNCT06064006PART A: Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0487-0111, Placebo (NNC0487-0111) | Obesity, Overweight | 125 | 2024-11-27actual | — | 2025-11-19 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney FunctionNCT06370819Area under the curve (AUC)0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with normal function, and mild, moderate and severe impairmentOpen-label · Treatment | Phase 1 | Completed | Drug: NNC0519-0130 | Diabetes Mellitus, Type 2 | 36 | 2024-11-27actual | — | 2026-04-07 |
| A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)NCT04865770results2026-01-14Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (Semaglutide) | Diabetes Mellitus, Type 2, Chronic Kidney Disease | 106 | 2024-11-21actual | — | 2026-02-10 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical PracticeNCT05443568observationalChange in HbA1c (Glycated haemoglobin) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 155 | 2024-11-16actual | — | 2025-10-06 |
| A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsNCT05306418Number of treatment emergent adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: Mim8 | Haemophilia A With or Without Inhibitors | 70 | 2024-11-13actual | — | 2025-11-13 |
| A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese ParticipantsNCT06581627AUC0-inf,etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single doseOpen-label · Treatment | Phase 1 | Completed | Drug: Etavopivat | Healthy Volunteers, Sickle Cell Disease, Thalassemia | 24 | 2024-10-31actual | — | 2025-12-29 |
| A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)NCT05646706results2026-04-23Semaglutide 7.2 mg Versus Placebo: Relative Change in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Semaglutide, Placebo | Obesity | 1,407 | 2024-10-30actual | — | 2026-04-23 |
| A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightNCT05649137results2026-04-27Relative Change in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Semaglutide, Placebo | Obesity, Diabetes Mellitus, Type 2 | 512 | 2024-10-28actual | — | 2026-04-27 |
| A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian MenNCT06542536Number of treatment emergent adverse events (TEAEs) after single dose of oral monlunabantRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Monlunabant, Placebo (monlunabant) | Obesity | 73 | 2024-10-25actual | — | 2025-11-18 |
| DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in ItalyNCT05755360observationalAbsolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 291 | 2024-10-21actual | — | 2025-10-02 |
| A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877Relative change in energy intake during ad libitum lunch, evening meal and snackboxRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Cagrilintide, Semaglutide, Placebo | Obesity | 62 | 2024-10-16actual | — | 2026-01-08 |
| A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cagrilintide, Semaglutide, Atorvastatin, Warfarin | Obesity | 34 | 2024-10-16actual | — | 2026-05-19 |
| Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and ObesityNCT05444153Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No)Randomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Semaglutide, Empagliflozin | Diabetes Mellitus, Type 2 | 0 | 2024-10-02 | — | 2022-11-14 |
| A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in JapanNCT02670213observationalAdverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with NovoThirteen®, comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of therapeutic effect | — | Completed | Drug: recombinant factor XIII | Congenital Bleeding Disorder, Congenital FXIII Deficiency | 8 | 2024-09-30actual | — | 2025-08-29 |
| Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational StudyNCT06288399observationalProportion of Obesity Related Comorbidities (ORC, existing/newly diagnosed) among adult people with obesity (BMI above or equal to 30 kg/m2) over a period of 12 months across the Gulf region in primary and secondary hospitals as well as obesity clinics | — | Completed | Other: No treatment given | Obesity | 1,316 | 2024-09-30actual | — | 2025-10-15 |
| Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone DeficiencyNCT02616562results2026-01-16Height Velocity (HV) (cm/Year) During the First 26 Weeks of Treatment, Measured as Standing Height With StadiometerRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: somapacitan, Norditropin® FlexPro® pen | Growth Hormone Disorder, Growth Hormone Deficiency in Children | 76 | 2024-09-26actual | — | 2026-01-16 |
| A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical PracticeNCT05069545observationalChange in time in range (3.9-10 mmol/L) | — | Completed | Drug: Insulin degludec, Fast-acting insulin aspart | Diabetes Mellitus, Type 1 | 411 | 2024-09-10actual | — | 2025-12-31 |
| A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104Part A: AUC 0-infinity (∞), single dose (SD), cagri: The area under the cagrilintide plasma concentration-time curve fromtime 0 to infinity after a single doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cagrilintide | Hepatic Impairment, Healthy Volunteers | 32 | 2024-09-06actual | — | 2025-12-12 |
| A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326results2025-09-22Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal StrokeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 9,651 | 2024-08-23actual | — | 2025-12-11 |
| A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseNCT05891496results2026-02-24Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo | Alzheimers Disease | 23 | 2024-08-19actual | — | 2026-08-18 |
| Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 DiabetesNCT06517784observationalThe barriers toward insulin initiation among HCPs & patients | — | Completed | Other: No treatment given | Type 2 Diabetes | 752 | 2024-08-16actual | — | 2024-08-28 |
| A Research Study of a New Medicine (NNC0650-0013) in Healthy MenNCT06284798S.C. Cohort: Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0650-0013 A, Placebo | Healthy Participants | 11 | 2024-07-25actual | — | 2025-12-05 |
| A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)NCT05878938Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 3 | Completed | Drug: NNC0365-3769 (Mim8) PPX | Haemophilia A, Haemophilia A With Inhibitors | 61 | 2024-07-18actual | — | 2025-12-08 |
| A Research Study of the Effect of Food on Etavopivat in Healthy ParticipantsNCT06433661AUC0-inf, etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Etavopivat | Healthy Volunteers Sickle Cell Disease, Thalassemia | 16 | 2024-07-06actual | — | 2025-10-10 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical PracticeNCT05443334observationalChange in HbA1c | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 465 | 2024-07-04actual | — | 2025-09-24 |
| A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.NCT06133270Part A: Number of treatment-emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0560-0004, Placebo (NNC0560-0004) | Healthy Volunteers - Liver Diseases | 51 | 2024-07-04actual | — | 2025-08-20 |
| A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular DiseaseNCT05873660observationalOverweight and obesity among patients with established CVD pooled across all countries | — | Completed | Other: No treatment given | Obesity, Overweight | 5,360 | 2024-06-24actual | — | 2024-07-11 |
| A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and InflammationNCT05379829Area under the ziltivekimab plasma concentration-time curve in a 4-week dosing interval, multiple doses [MD] (AUCτ,MD)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Ziltivekimab, Placebo | Chronic Kidney Disease and Systemic Inflammation | 24 | 2024-06-12actual | — | 2025-12-31 |
| A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy PeopleNCT06291285AUC0-inf,DEC,SD: Area under the plasma decitabine concentration-time curve after a single doseRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Decitabine-THU, Decitabine-THU | Healthy Volunteers | 44 | 2024-06-10actual | — | 2025-12-29 |
| A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 DiabetesNCT04560998results2025-07-08Change in Maximum Walking Distance on a Constant Load Treadmill TestRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2, Peripheral Arterial Disease | 792 | 2024-06-05actual | — | 2026-06-05 |
| A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in IndiaNCT05502562observationalChange in Glycated haemoglobin A1c (HbA1c) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 388 | 2024-06-03actual | — | 2024-09-19 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical PracticeNCT05473286observationalChange in Glycated haemoglobin (HbA1c ) | — | Withdrawnsponsor's stated reason: Rybelsus® was not launched in Germany during the planned duration of NN9924-4540 study. | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 0 | 2024-05-16 | — | 2022-09-29 |
| A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among NephrologistsNCT06322641observationalNephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation | 300 | 2024-05-10actual | — | 2024-07-26 |
| Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting InsulinNCT06592950observationalT2DM patient preferences for a once weekly insulin treatment | — | Completed | Other: No treatment given, No treatment given | Type-2 Diabetes Mellitus (T2DM) | 513 | 2024-04-29actual | — | 2024-09-19 |
| Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy RangeNCT05564117results2026-02-25Percentage Change in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo semaglutide | Overweight, Obesity | 307 | 2024-04-18actual | — | 2026-02-25 |
| A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy ParticipantsNCT05996874AUC0-24h,sema,Day10: Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosingRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide | Healthy Participants | 121 | 2024-04-18actual | — | 2025-09-24 |
| A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia BNCT05365217results2025-05-31Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis (PPX)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Nonacog beta pegol | Haemophilia B | 30 | 2024-04-11actual | — | 2026-01-12 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical PracticeNCT05316662observationalChange in HbA1c | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 187 | 2024-04-06actual | — | 2025-09-24 |
| A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.NCT05363774Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) partRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: NNC0519-0130, Placebo (NNC0519-0130) | Healthy Volunteers (Diabetes Mellitus, Type 2) | 161 | 2024-04-02actual | — | 2025-12-31 |
| Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)NCT06351748observationalChange in Haemoglobin A1c (HbA1c) level | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 34,238 | 2024-03-29actual | — | 2025-04-16 |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin IcodecNCT05352815results2025-04-03Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: IcoSema, Insulin icodec | Diabetes Mellitus, Type 2 | 1,291 | 2024-03-19actual | — | 2025-12-04 |
| A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsNCT05053139Number of treated bleedsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: NNC0365-3769 (Mim8) | Haemophilia A, Haemophilia A With Inhibitors | 281 | 2024-03-11actual | — | 2025-12-08 |
| A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)NCT05823948results2026-04-30Change in Glycosylated Haemoglobin (HbA1c)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin Icodec | Diabetes Mellitus, Type 2 | 51 | 2024-03-06actual | — | 2026-04-30 |
| A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy ParticipantsNCT05784402AUC0-24h,semaglutide,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide J, Semaglutide C | Healthy Participants | 264 | 2024-02-23actual | — | 2025-12-02 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IIINCT06097390Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curveRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide | Healthy Participants | 121 | 2024-02-22actual | — | 2025-07-17 |
| A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and TeenagersNCT05790681Area under the serum insulin icodec concentration-time curve after a single dose (AUCIco,0-inf,SD)Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 18 | 2024-02-08actual | — | 2026-04-09 |
| Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 DiabetesNCT05533632results2025-02-10Number of Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 104 | 2024-01-18actual | — | 2025-09-24 |
| A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseNCT03819153results2025-03-20Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV DeathRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 3,533 | 2024-01-09actual | — | 2025-03-20 |
| A Research Study on How NNC0487-0111 Works in People With Overweight or ObesityNCT05369390Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0487-0111 A, NNC0487-0111 B · Other: Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A) | Obesity | 144 | 2024-01-09actual | — | 2025-06-15 |
| A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine ZiltivekimabNCT05721989AUC0-inf, zilti, SD: Area under the ziltivekimab serum concentration-time curve from 0 hours and extrapolated to infinity after a single doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ziltivekimab B, Ziltivekimab D, Ziltivekimab C | Healthy Participants | 267 | 2024-01-08actual | — | 2025-12-30 |
| A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate FormulationsNCT05766709AUC 0-168 hour (h), 0499, steady state (SS): Area under the NNC0194-0499 concentration time curve during a dosing interval (0-168 hours) at steady state after dosing of NNC0194-0499 in combination with semaglutideRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL), NNC0194-0499/Semaglutide A (40/0.33mg/mL) | Non-alcoholic Steatohepatitis | 53 | 2024-01-05actual | — | 2024-02-29 |
| A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityNCT06049329Number of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0487-0111, Placebo (NNC0487-0111) | Obesity | 36 | 2023-12-15actual | — | 2025-03-05 |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)NCT05259033results2025-01-17Change From Baseline in Glycosylated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: IcoSema, Semaglutide 1 mg | Diabetes Mellitus, Type 2 | 683 | 2023-12-13actual | — | 2026-06-12 |
| Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®NCT04334057observationalNumber of adverse reactions (ARs) reported during the observation period | — | Completed | Drug: Turoctocog alfa pegol | Haemophilia A | 23 | 2023-11-30actual | — | 2026-06-15 |
| A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and PolandNCT05795166observationalPercentage of patients with at least one obesity related comorbidity of interest for obesity classes I, II and III pooled across all countries | — | Completed | Other: No treatment given | Obesity | 1,241 | 2023-11-30actual | — | 2024-09-19 |
| Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.NCT01467427results2017-11-17Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: nonacog beta pegol | Congenital Bleeding Disorder, Haemophilia B | 25 | 2023-11-17actual | — | 2025-12-23 |
| A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.NCT04970654results2024-12-10Height VelocityRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: somapacitan, Norditropin® | Growth Hormone Deficiency in Children | 110 | 2023-11-17actual | — | 2026-01-06 |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)NCT05013229Change in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: IcoSema, Insulin glargine, insulin aspart | Diabetes Mellitus, Type 2 | 679 | 2023-11-14actual | — | 2025-12-02 |
| A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionNCT05727644AUC0499,0-∞,SD: Area under the NNC0194-0499 serum concentration-time curve after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0194-0499 | Non-alcoholic Steatohepatitis (NASH) | 42 | 2023-11-10actual | — | 2023-12-06 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical PracticeNCT05230615observationalChange in HbA1c (Glycated haemoglobin) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 458 | 2023-10-31actual | — | 2025-09-24 |
| Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityNCT04998136results2025-04-03Change in Body Weight (%) : In-trial Observation PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide 2.4 mg, Placebo (semaglutide 2.4 mg) | Obesity | 150 | 2023-10-16actual | — | 2025-12-30 |
| A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and CartridgeNCT05681845AUC0-112 days, SD: area under the Mim8 plasma concentration-time curve from time 0 until 112 days after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0365-3769 (Mim8) | Haemophilia A | 205 | 2023-10-13actual | — | 2025-10-14 |
| A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and OverweightNCT05486065results2024-11-05Change in Glycated Haemoglobin (HbA1c)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide, Placebo | Diabetes Mellitus, Type 2 | 245 | 2023-10-12actual | — | 2025-12-12 |
| Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Semaglutide, Placebo (Semaglutide) | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | 617 | 2023-10-11actual | — | 2025-11-26 |
| A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese MenNCT05870670AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment PeriodRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0519-0130, Placebo | Diabetes Mellitus, Type 2 | 22 | 2023-10-07actual | — | 2025-06-18 |
| A Research Study Investigating Mim8 in People With Haemophilia ANCT04204408Part 1: Number of treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NNC0365-3769 (Mim8), Placebo (Mim8) | Healthy Volunteers, Haemophilia A With or Without Inhibitors | 275 | 2023-10-06actual | — | 2025-12-19 |
| Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by GenderNCT06260696observationalScore on IWQOL-Lite validated | — | Completed | Other: No treatment is given | Overweight, Obesity | 3,000 | 2023-10-05actual | — | 2024-02-15 |
| Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi ArabiaNCT05642533observationalProportion of people with obesity without a history of Type 2 diabetes (T2D) who have Cardiovascular disease (CVD)s (pre-existing or newlydiagnosed) | — | Completed | Other: No treatment given | Obesity and Cardiovascular Risk | 1,061 | 2023-09-14actual | — | 2025-12-30 |
| Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-surveyNCT05765890observationalUnaided awareness | — | Completed | Other: No treatment given | Non-alcoholic Steatohepatitis (MASH), Non-alcoholic Fatty Liver Disease (MASLD) | 675 | 2023-09-12actual | — | 2023-10-11 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical PracticeNCT04862923observationalChange in glycated haemoglobin (HbA1c) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 336 | 2023-08-31actual | — | 2025-09-24 |
| A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) At 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose LevelRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Cagrilintide, Cagrilintide Placebo, Moxifloxacin, Moxifloxacin Placebo | Obesity | 107 | 2023-08-12actual | — | 2024-11-01 |
| A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesNCT05478252results2024-10-09Change in Glycosylated Haemoglobin (HbA1c)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide J, Semaglutide B | Diabetes Mellitus, Type 2 | 388 | 2023-08-09actual | — | 2025-12-12 |
| Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisNCT05064735results2024-08-13Percentage Change in Body WeightRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: semaglutide 2.4 mg, semaglutide 2.4 mg (placebo) | Obesity | 407 | 2023-07-24actual | — | 2025-11-17 |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With ObesityNCT05132088results2026-08-14Percent Change From Baseline in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: semaglutide 50 mg, placebo (semaglutide) | Overweight and Obesity | 201 | 2023-07-11actual | — | 2026-08-14 |
| O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and KuwaitNCT05716724observationalChange in glycated haemoglobin (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 288 | 2023-07-09actual | — | 2024-01-11 |
| A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy PeopleNCT05227196AUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6 | Healthy Volunteers, Type 2 Diabetes | 546 | 2023-06-28actual | — | 2024-09-19 |
| Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597results2024-08-30Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal StrokeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Overweight, Obesity | 17,604 | 2023-06-21actual | — | 2024-08-30 |
| A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese MenNCT05742919AUC0-∞, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0194-0499, NNC0194-0499, NC0194-0499 | Non-alcoholic Fatty Liver Disease | 24 | 2023-06-13actual | — | 2024-06-11 |
| Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia ANCT02137850results2024-10-31Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 124 | 2023-06-07actual | — | 2025-12-23 |
| A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) DoseNCT05689099AUC0-last,sema 0.5mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after single dose of subcutaneous semaglutide 0.5 mgRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL | Diabetes Mellitus, Type 2, Healthy Participants | 20 | 2023-05-30actual | — | 2024-10-15 |
| A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide TabletsNCT04817644Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)Open-label · Treatment | Phase 1 | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 14 | 2023-05-26actual | — | 2025-03-11 |
| A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among CardiologistsNCT05755373observationalCardiologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD. Multi-select from a defined list. | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 602 | 2023-05-15actual | — | 2023-06-09 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical PracticeNCT04537637observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 99 | 2023-05-08actual | — | 2025-09-24 |
| A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in CroatiaNCT05479591observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Withdrawnsponsor's stated reason: Sponsor decision | Drug: IDegLira | Diabetes Mellitus, Type 2 | 0 | 2023-04-30 | — | 2022-11-01 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical PracticeNCT05443191observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 50 | 2023-04-27actual | — | 2025-12-30 |
| A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or TogetherNCT05435677AUCIco,0-tz:Area under the serum insulin icodec concentration-time curve after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: IcoSema, insulin icodec, semaglutide | Diabetes Mellitus, Type 2 | 20 | 2023-04-25actual | — | 2025-03-21 |
| A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.NCT05542420observationalBMI (body mass index) | — | Completed | Other: No treatment given | Diabetes Mellitus, Type 2 | 3,000 | 2023-04-20actual | — | 2024-09-19 |
| Persons With Obesity (PwO) Exploratory ResearchNCT05736120observationalDescription of perceptions, behaviours and awareness related to obesity and obesity management among people living with obesity. | — | Completed | Other: No treatment given | Obesity | 46 | 2023-04-19actual | — | 2023-05-12 |
| Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesityNCT04788511results2024-06-11Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Obesity | 529 | 2023-04-18actual | — | 2025-12-05 |
| Attitudes and Unmet Needs Among Type 2 Diabetes PatientsNCT05737810observationalCurrent medication burden | — | Completed | Other: No treatment given | Type 2 Diabetes | 700 | 2023-04-17actual | — | 2023-05-15 |
| China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)NCT05221580observationalChange in Glycosylated Haemoglobin (HbA1c) | — | Completed | Drug: Ryzodeg® | Diabetes Mellitus, Type 2 | 887 | 2023-03-31actual | — | 2024-06-14 |
| Awareness, Care & Treatment In Obesity ManagementNCT05690789observationalWeight loss motivators | — | Completed | Other: No treatment given | Obesity | 1,688 | 2023-03-31actual | — | 2023-06-15 |
| Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational ActivitiesNCT04584892observationalIndividual prophylaxis (PPX) regimen with turoctocog alfa: Every second day, or three times a week (3TW), or twice a week (2TW) | — | Completed | Drug: Turoctocog alfa | Haemophilia A | 18 | 2023-03-27actual | — | 2023-11-28 |
| A Research Study of a New Medicine NNC0113-6856 in Healthy MalesNCT05521256Number of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0113-6856, Placebo | Healthy Volunteers, Type 2 Diabetes | 70 | 2023-03-27actual | — | 2025-12-31 |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)NCT05035095results2026-05-07Percentage Change in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Oral semaglutide, Placebo (semaglutide) | Obesity, Overweight | 667 | 2023-03-24actual | — | 2026-05-07 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical PracticeNCT05230589observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 194 | 2023-03-13actual | — | 2025-09-24 |
| A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One TabletNCT05429593AUC0-24h,sema,ss: area under the semaglutide plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin | Healthy Volunteers | 152 | 2023-03-10actual | — | 2024-08-07 |
| Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesNCT04707469results2024-04-03Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 1,606 | 2023-03-07actual | — | 2025-12-09 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical PracticeNCT04601753observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 194 | 2023-03-03actual | — | 2025-09-24 |
| A Research Study Looking at New Protein-based Tablets in Healthy Male ParticipantsNCT05129891AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide D, Semaglutide G, Semaglutide H, Semaglutide I, NNC0385-0434 B, NNC0385-0434 C, NNC0385-0434 D, NNC0385-0434 E | Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes | 384 | 2023-02-26actual | — | 2024-05-29 |
| A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 DiabetesNCT05144984results2026-04-09Change From Baseline in Glycosylated Haemoglobin (HbA1c)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 500 | 2023-02-13actual | — | 2026-04-09 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical PracticeNCT04878393observationalChange in glycated haemoglobin (HbA1c) | — | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 650 | 2023-02-09actual | — | 2025-09-24 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical PracticeNCT04537624observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 194 | 2023-01-11actual | — | 2024-09-19 |
| Research Study Looking at How Well Semaglutide Works in People Living With Obesity and PrediabetesNCT05040971results2024-10-28Change in Body Weight (Percentage [%])Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide 2.4 mg, Placebo | Obesity | 207 | 2023-01-06actual | — | 2026-01-29 |
| A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in ItalyNCT04666987observationalChange in Glycated Haemoglobin (HbA1c) | — | Completed | Drug: Insulin degludec and liraglutide (IDegLira) | Diabetes Mellitus, Type 2 | 359 | 2022-12-30actual | — | 2024-04-03 |
| Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)NCT05082116results2024-01-18Number of Bleeding Episodes Per Year (Annualised Bleeding Rate)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: turoctocog alfa pegol (N8-GP) | Haemophilia A | 36 | 2022-12-28actual | — | 2026-01-06 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical PracticeNCT04601740observationalChange in Glycated haemoglobin (HbA1c ) | — | Completed | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 145 | 2022-12-19actual | — | 2025-09-24 |
| A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 DiabetesNCT04032197Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteriesRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 101 | 2022-12-16actual | — | 2025-04-29 |
| A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With ObesityNCT04969939results2026-01-08Part 1: Number of Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg | Obesity | 120 | 2022-12-06actual | — | 2026-01-08 |
| Awareness, Care & Treatment In Obesity Management - An Observation in Mainland ChinaNCT05428501observationalWeight loss motivators | — | Completed | Other: no treatment given | Obesity | 8,000 | 2022-11-30actual | — | 2024-09-19 |
| A Study of FT-7051 in Men With MCRPCNCT04575766Incidence of dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: FT-7051 | Metastatic Castration-resistant Prostate Cancer | 25 | 2022-11-08actual | — | 2023-08-09 |
| A Study Investigating the Safety and Performance of DV3395, a New Concept Device for the Delivery of Medicine.NCT05314283Number of adverse eventsOpen-label · Other | Phase 1 | Completed | Device: DV3395 C1 | Healthy Volunteers, Medical Device | 65 | 2022-11-08actual | — | 2024-11-19 |
| Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia BNCT02141074results2023-12-29Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: nonacog beta pegol | Congenital Bleeding Disorder, Haemophilia B | 54 | 2022-10-27actual | — | 2025-12-23 |
| GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.NCT04838743observationalChange in local laboratory measured HbA1c (Glycated haemoglobin ) | — | Completed | Drug: IDegLira | Diabetes Mellitus, Type 2 | 244 | 2022-10-26actual | — | 2025-12-31 |
| A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese MenNCT05498610AUC0-∞,NNC0480-0389,SD Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity after a single dose (SD)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0480 0389, Semaglutide | Diabetes Mellitus, Type 2 | 24 | 2022-10-12actual | — | 2023-12-26 |
| INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical RecordsNCT05438186observationalRelative change in body weight | — | Withdrawnsponsor's stated reason: No participants enrolled since study start. | Drug: Liraglutide | Obesity | 0 | 2022-09-30 | — | 2023-01-25 |
| A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With ObesityNCT05236517Relative change in energy intake during ad libitum lunchRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide C Dose 4, Semaglutide C Dose 5 (50 mg), Placebo (Semaglutide C), Placebo ( Semaglutide D) | Obesity | 60 | 2022-09-29actual | — | 2024-09-19 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical PracticeNCT04559815observationalChange in Glycated haemoglobin (HbA1c) | — | Completed | Drug: Oral Semaglutide | Diabetes Mellitus, Type 2 | 194 | 2022-09-14actual | — | 2025-12-05 |
| In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care DatabaseNCT03479762observationalNumber of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only) | — | Completed | Drug: Liraglutide | Obesity, Overweight | 105 | 2022-09-12actual | — | 2022-11-25 |
| A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With ObesityNCT05254158AUC0-∞, NNC0174-0833: The area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0174 0833 | Overweight and Obesity | 24 | 2022-09-07actual | — | 2023-11-07 |
| An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and AfricaNCT05317845observationalProportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope | — | Completed | Other: No treatment given | Diabetes Mellitus, Type 2 | 4,089 | 2022-08-31actual | — | 2023-03-28 |
| A Clinical Trial Looking at the Comparability of 2 Different Forms of SemaglutideNCT05232708AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mgRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide B, 1.34 mg/mL | Healthy Volunteers (Diabetes Mellitus, Type 2) | 18 | 2022-08-30actual | — | 2024-01-26 |
| A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin PumpNCT05262595AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D, Faster aspart | Diabetes Mellitus, Type 1 | 19 | 2022-08-29actual | — | 2023-10-12 |
| Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.NCT04251156results2024-11-29Change From Baseline in Body Weight (Percentage [%])Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Overweight, Obesity, Diabetes Mellitus, Type 2 | 375 | 2022-08-23actual | — | 2026-01-29 |
| A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After MenopauseNCT05153564Area under the ethinylestradiol plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,EE,SS)Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL, NNC0480-0389 30 mg/mL, Microgynon® | Diabetes Mellitus, Type 2 | 27 | 2022-08-13actual | — | 2023-11-13 |
| A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04760626results2025-08-26Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL | Diabetes Mellitus, Type 2 | 1,085 | 2022-08-12actual | — | 2026-08-11 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney FunctionNCT05015894AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single doseOpen-label · Treatment | Phase 1 | Completed | Drug: NNC0480-0389 | Diabetes Mellitus, Type 2 | 42 | 2022-08-02actual | — | 2023-11-13 |
| Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal AtrophyNCT05243823observationalFirst time occurrence of endometrial cancer (yes/no) during time in cohort from entry (start of treatment) to exit (end of study period, occurrence of any other cancer (except non-melanoma skin cancer), date of emigration or date of death) | — | Completed | Drug: Vagifem®, Non-Vagifem® LDVE, Estradiol | Postmenopausal Vaginal Atrophy | 500,000 | 2022-07-31actual | — | 2022-12-23 |
| A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)NCT05468632observationalChange in glycated haemoglobin (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 314 | 2022-07-31actual | — | 2023-02-14 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IINCT05333107AUC0-24h,NNC0385-0434,day10; area under the plasma concentrationtime curve during a dosing intervalRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B | Healthy Volunteers; High Cholesterol | 152 | 2022-07-22actual | — | 2024-07-12 |
| A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 DiabetesNCT04698018AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutesRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Faster Aspart, Novo Rapid | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 23 | 2022-07-20actual | — | 2025-12-04 |
| A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney FunctionNCT05094934AUC0-24h,0434,Day10: the area under the NNC0385-0434 plasma concentration-time curve from time 0 to 24 hours after last dose of oral NNC0385-0434Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: NNC0385-0434 A 100 mg | Chronic Kidney Disease | 60 | 2022-07-15actual | — | 2023-12-26 |
| Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in ColombiaNCT05324462observationalChange in local laboratory measured Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: IDegLira | Diabetes Mellitus, Type 2 | 175 | 2022-07-15actual | — | 2022-11-09 |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575results2023-07-27Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide), Placebo (cagrilintide) | Diabetes Mellitus, Type 2 | 92 | 2022-07-07actual | — | 2025-12-23 |
| Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With DiabetesNCT04588259results2024-03-20Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%])Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Faster aspart, Insulin aspart, Insulin degludec | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 331 | 2022-07-05actual | — | 2025-12-04 |
| An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical PracticeNCT03987802observationalAdverse Events (AEs) | — | Completed | Drug: Faster-acting insulin aspart | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 42 | 2022-06-28actual | — | 2026-04-09 |
| A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)NCT04795531results2024-12-04Change in Glycated Haemoglobin (HbA1c)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec | Diabetes Mellitus, Type 2 | 588 | 2022-06-23actual | — | 2026-06-12 |
| A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)NCT04880850results2025-07-02Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin icodec, Insulin glargine, Insulin aspart | Diabetes Mellitus, Type 2 | 582 | 2022-06-16actual | — | 2025-12-04 |
| A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or ObesityNCT04010786For single dose (SD) cohorts: Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0247-0829, Placebo (NNC0247-0829) | Overweight, Obesity | 103 | 2022-06-11actual | — | 2024-01-23 |
| Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450results2023-08-15Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Semaglutide, Standard of care | Diabetes Mellitus, Type 2 | 1,278 | 2022-06-09actual | — | 2024-07-03 |
| A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04460885results2025-06-12Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin icodec, Insulin glargine | Diabetes Mellitus, Type 2 | 984 | 2022-05-29actual | — | 2025-12-04 |
| Awareness, Care & Treatment In Obesity Management - An Observation in Asia PacificNCT05250427observationalWeight loss motivators for improving health of PLwO | — | Completed | Other: No treatment given | Obesity | 12,404 | 2022-05-23actual | — | 2022-06-14 |
| A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy PeopleNCT05127473Number of treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Mim8 B, 10 mg/mL, Mim8 B, 100 mg/mL, Mim8 B, placebo | Healthy Volunteers - Haemophilia A | 66 | 2022-05-14actual | — | 2023-11-01 |
| A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It WorksNCT05134987AUCPG,0.5-2h Area under the plasma glucose-time curve at steady concentrationsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0363-0845, Insulin detemir | Diabetes Mellitus, Type 1 | 30 | 2022-05-06actual | — | 2022-11-04 |
| A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)NCT04848480results2025-06-12Change in Glycosylated Haemoglobin (HbA1c) at Week 26Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: insulin icodec, insulin degludec, insulin aspart | Diabetes Mellitus, Type 1 | 582 | 2022-04-28actual | — | 2025-12-04 |
| A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart DiseaseNCT04992065results2025-06-08Percentage Change in Low-density Lipoprotein (LDL)-CholesterolRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, NNC0385-0434 A 100 mg, Evolocumab 140 mg/mL, Repatha® · Other: Placebo I A (for NNC0385-0434 A 15 mg), Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg) | Atherosclerotic Cardiovascular Disease | 267 | 2022-04-26actual | — | 2025-06-08 |
| A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 DiabetesNCT04582435AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady stateOpen-label · Treatment | Phase 1 | Completed | Drug: Insulin Icodec | Diabetes Mellitus, Type 2 | 46 | 2022-04-22actual | — | 2023-09-18 |
| A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in SwitzerlandNCT05153590observationalRelative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no) | — | Completed | Drug: Saxenda® | Obesity or Overweight | 269 | 2022-04-15actual | — | 2022-11-17 |
| Awareness, Care & Treatment In Obesity Management - An Observation in SwitzerlandNCT05232786observationalWeight loss motivators | — | Completed | Other: No treatment given | Obesity | 1,152 | 2022-04-08actual | — | 2022-10-26 |
| A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy ParticipantsNCT05091073AUC0-24h,0434,Day10: the area under the NNC0385-0434 plasma concentration-time curve from 0 to 24 h after last dose of oral NNC0385-0434Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0385-0434 | Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers | 73 | 2022-04-07actual | — | 2023-12-26 |
| A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 DiabetesNCT04857398Area under the serum insulin icodec concentration-time curve during one dosing interval at steady stateOpen-label · Treatment | Phase 1 | Completed | Drug: insulin icodec | Diabetes Mellitus, Type 2 | 24 | 2022-04-06actual | — | 2023-05-17 |
| A Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityNCT04102189results2023-04-18Change in Body Mass Index (BMI) (Percentage [%])Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide · Other: Placebo | Overweight, Obesity | 201 | 2022-03-25actual | — | 2025-12-11 |
| A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver DiseaseNCT04597697AUC,Ico,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 25 | 2022-03-24actual | — | 2024-07-12 |
| First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With DiabetesNCT04259801Number of treatment emergent adverse events (TEAE) in Part 1Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0480-0389, Semaglutide, Placebo (NNC0480-0389), Placebo (semaglutide) | Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2 | 152 | 2022-03-16actual | — | 2023-11-13 |
| Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy PeopleNCT04524832Area under the semaglutide plasma concentration - time curve during a dosing interval at steady state (AUC0-24h,sema,SS)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Oral semaglutide | Diabetes Mellitus, Type 2 | 290 | 2022-02-25actual | — | 2023-10-10 |
| A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily InsulinNCT04770532results2025-02-20Change in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin degludec, Insulin Icodec | Diabetes Mellitus, Type 2 | 526 | 2022-01-27actual | — | 2025-12-15 |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078AUC0-168h,cagri,2.4/2.4mg,SS area under the cagrilintide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mgRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cagrilintide, semaglutide, Cagrilintide and semaglutide | Obesity & Overweight | 40 | 2022-01-19actual | — | 2025-12-12 |
| A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese MenNCT05003440Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0385-0434, Placebo | Healthy Volunteers, Atherosclerotic Cardiovascular Disease | 36 | 2022-01-19actual | — | 2024-01-17 |
| Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)NCT03435627observationalNumber of adverse drug reactions (ADR) | — | Completed | Drug: Somatropin | Genetic Disorder, Noonan Syndrome | 71 | 2022-01-18actual | — | 2022-11-14 |
| A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.NCT05178550Change from baseline in Lipoprotein Lipase (LPL) levels before and after heparin exposure both in fasted and postprandial stateRandomized · Open-label · Other | Early Phase 1 | Completed | Drug: Heparin | Healthy Volunteers | 12 | 2022-01-11actual | — | 2023-05-22 |
| A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy PeopleNCT05046873AUC0-∞,sema,SD: Area under the semaglutide plasma concentration-time curve after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, semaglutide 1.34 mg/mL (placebo), Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL | Diabetes Mellitus, Type 2 | 16 | 2022-01-05actual | — | 2023-07-03 |
| Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)NCT05013359observationalAttitudes about obesity, attitudes about people with obesity, and beliefs about the impact of obesity | — | Completed | Other: No treatment given | Obesity | 12,987 | 2021-12-13actual | — | 2022-02-02 |
| A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin GlargineNCT04575181Change in flow mediated dilationRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0268-0965, Insulin glargine, Placebo (NNC0268-0965), Placebo (insulin glargine) | Diabetes Mellitus, Type 2 | 86 | 2021-12-10actual | — | 2024-01-10 |
| Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsNCT02773355observationalFrequency of pancreatitis | — | Completed | Drug: liraglutide 3.0 mg | Obesity | 27 | 2021-11-30actual | — | 2026-04-13 |
| A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes MellitusNCT04655690Number of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0471-0119, Fast-acting insulin aspart | Diabetes Mellitus, Type 1 | 48 | 2021-11-26actual | — | 2023-01-03 |
| Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in LebanonNCT04892069observationalChange in Glycated Haemoglobin (HbA1c) | — | Completed | Drug: Insulin Degludec/Insulin Aspart | Diabetes Mellitus, Type 2 | 60 | 2021-11-18actual | — | 2022-11-14 |
| A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)NCT03811535results2023-08-04Height Velocity: In-trial Observation PeriodRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Somapacitan, Norditropin® | Growth Hormone Deficiency in Children | 200 | 2021-11-10actual | — | 2026-05-22 |
| A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 DiabetesNCT04017832results2023-09-29Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Oral semaglutide, Sitagliptin, Placebo (oral semaglutide), Placebo (sitagliptin) | Diabetes Mellitus, Type 2 | 1,441 | 2021-10-27actual | — | 2024-10-01 |
| A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)NCT03741881observationalThe number of treated bleeding episodes | — | Completed | Other: No treatment given | Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors | 231 | 2021-10-25actual | — | 2021-11-23 |
| A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 DiabetesNCT03945656Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulinRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: insulin icodec, Insulin glargine | Diabetes Mellitus, Type 2 | 43 | 2021-09-27actual | — | 2023-09-06 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)NCT04083820observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: semaglutide | Diabetes Mellitus, Type 2 | 521 | 2021-09-27actual | — | 2023-03-28 |
| A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 DiabetesNCT04582448AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single doseRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 25 | 2021-09-27actual | — | 2023-01-20 |
| A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 DiabetesNCT04109547results2023-09-14Change From Baseline in Glycosylated Haemoglobin (HbA1c)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Oral semaglutide, Placebo | Diabetes Mellitus, Type 2 | 521 | 2021-09-23actual | — | 2024-09-19 |
| Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.NCT04626505results2026-05-06Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ziltivekimab, Placebo (ziltivekimab) | Chronic Kidney Disease, Inflammation, Cardiovascular Risk | 36 | 2021-08-03actual | — | 2026-05-06 |
| A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in RussiaNCT04315688observationalChange in laboratory measured glycated haemoglobin (HbA1c) (% point) | — | Completed | Drug: insulin degludec | Diabetes Mellitus, Type 2 | 494 | 2021-08-02actual | — | 2021-08-23 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical PracticeNCT04094415observationalChange in Glycated Haemoglobin A1c (HbA1c) (measured in percent) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 581 | 2021-07-28actual | — | 2023-02-23 |
| A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese MenNCT04878406Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0480-0389, Placebo (NNC0480-0389), Semaglutide, Placebo (Semaglutide) | Healthy Volunteers Type 2 Diabetes | 24 | 2021-07-20actual | — | 2023-05-17 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical PracticeNCT04067999observationalChange in Glycated Haemoglobin A1c (HbA1c) (measured in percent) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 230 | 2021-07-19actual | — | 2021-09-24 |
| A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in ChinaNCT04227431observationalChange in glycosylated haemoglobin (HbA1c) | — | Completed | Other: Insulin degludec | Diabetes Mellitus, Type 2 | 938 | 2021-07-17actual | — | 2024-03-20 |
| A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South KoreaNCT04656106observationalChange in HbA1c (Glycosylated Hemoglobin) | — | Completed | Drug: Ryzodeg® | Diabetes Mellitus, Type 2 | 200 | 2021-07-01actual | — | 2021-09-28 |
| A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in AlgeriaNCT03862690observationalChange in glycosylated haemoglobin A1c (HbA1c) | — | Withdrawnsponsor's stated reason: Sponsor decision | Drug: BIAsp 30 | Diabetes Mellitus, Type 2 | 0 | 2021-06-28 | — | 2020-07-20 |
| A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 DiabetesNCT04569994Number of treatment-emergent adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0363-0845, Placebo (NNC0363-0845), Insulin degludec | Healthy Volunteers, Diabetes Mellitus, Type 1 | 68 | 2021-06-23actual | — | 2023-06-27 |
| A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2NCT03847909results2024-05-22AUC From Day 90 To Day 180, Based on Percent Change From Baseline in 24-Hour UoxRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: DCR-PHXC, Sterile Normal Saline (0.9% NaCl) | Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease | 35 | 2021-06-21actual | — | 2024-05-22 |
| Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A PatientsNCT03179748observationalFrequency of adverse reactions | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 10 | 2021-06-16actual | — | 2021-11-15 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)NCT04261933observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: semaglutide | Diabetes Mellitus, Type 2 | 789 | 2021-05-25actual | — | 2023-03-28 |
| A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study CompoundsNCT04676906The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compoundsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0113-6861, NNC0113-6860, NNC0113-6891 | Healthy Volunteers, Type 2 Diabetes | 18 | 2021-04-28actual | — | 2023-04-27 |
| A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian MenNCT04722653Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0194-0499, Placebo (NNC0194-0499 ) | Non-alcoholic Steatohepatitis | 42 | 2021-04-27actual | — | 2022-04-05 |
| A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageNCT03987451results2024-05-29Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 WeeksRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Non-alcoholic Steatohepatitis | 71 | 2021-04-22actual | — | 2024-05-29 |
| A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different TimesNCT04513704Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Oral Semaglutide | Healthy Volunteers Type 2 Diabetes | 156 | 2021-04-20actual | — | 2023-05-12 |
| Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or ObesityNCT04074161results2022-04-27Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide) | Overweight, Obesity | 338 | 2021-03-27actual | — | 2023-05-19 |
| A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesNCT03689374results2022-05-04Change From Baseline in Glycated Haemoglobin (HbA1c)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Insulin aspart, Insulin glargine U100 | Diabetes Mellitus, Type 2 | 2,274 | 2021-02-22actual | — | 2022-11-14 |
| Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03693430results2022-03-23Percentage Change From Baseline (Week 0) to Week 104 in Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (Semaglutide) | Overweight, Obesity | 304 | 2021-01-29actual | — | 2023-07-06 |
| A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are ChineseNCT04016974AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady stateRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Oral semaglutide, Placebo | Healthy Volunteers, Diabetes Mellitus, Type 2 | 32 | 2021-01-23actual | — | 2024-07-12 |
| Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of BernNCT04444856observationalOccurrence of invasive procedures (yes/no). (Invasive procedures are defined as: uterine or iliac artery ligation, radiological arterial embolisation, uterine compression sutures, or hysterectomy.) | — | Completed | Drug: Eptacog alfa (activated) · Other: Standard of care | Severe Postpartum Haemorrhage | 225 | 2021-01-13actual | — | 2021-01-29 |
| A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney FunctionNCT04209049Area under the plasma NNC0174-0833 concentration-time curve after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0174-0833 | Overweight, Obesity | 33 | 2021-01-05actual | — | 2021-01-26 |
| A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide TabletsNCT04109508AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Oral semaglutide | Healthy Volunteers, Type 2 Diabetes | 278 | 2020-12-24actual | — | 2021-02-09 |
| Effect of Fiasp® in Type 1 Diabetes TreatmentNCT03895515observationalChange in percentage of time spent in glycaemic target range (TIR) | — | Completed | Drug: Fiasp® | Diabetes Mellitus, Type 1 | 178 | 2020-12-21actual | — | 2022-04-07 |
| Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 DiabetesNCT03377699results2022-04-27Last Planned Glycosylated Haemoglobin (HbA1c) Prior to DeliveryRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin degludec, Insulin Aspart, Insulin detemir | Diabetes, Diabetes Mellitus, Type 1 | 225 | 2020-12-17actual | — | 2023-01-20 |
| A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide TabletsNCT04097600AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Oral semaglutide | Healthy Volunteers, Type 2 Diabetes | 274 | 2020-12-16actual | — | 2022-09-13 |
| A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab EmiratesNCT03823339observationalChange in laboratory measured glycosylated haemoglobin A1c (HbA1c) | — | Completed | Drug: Insulin degludec/liraglutide | Diabetes Mellitus, Type 2 | 300 | 2020-12-14actual | — | 2021-09-22 |
| A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical PracticeNCT04042441observationalChange in local laboratory measured glycosylated haemoglobin (HbA1c) | — | Completed | Drug: Insulin Degludec/Insulin Aspart | Diabetes Mellitus, Type 2 | 1,122 | 2020-12-11actual | — | 2024-09-19 |
| A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia ANCT03528551results2021-11-26Number of Adverse Events ReportedNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Turoctocog alfa pegol, Turoctocog alfa pegol, Turoctocog alfa pegol | Congenital Bleeding Disorder, Haemophilia A | 160 | 2020-12-03actual | — | 2022-12-22 |
| A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.NCT03560336observationalIncidence of adverse events (AEs) by preferred term (PT) | — | Completed | Drug: Liraglutide | Obesity, Overweight | 758 | 2020-12-02actual | — | 2021-07-09 |
| A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi ArabiaNCT03785522observationalChange in glycated haemoglobin (HbA1c) (percentage) | — | Completed | Drug: Insulin degludec | Diabetes Mellitus, Type 2 | 597 | 2020-11-30actual | — | 2021-06-04 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)NCT03929679observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: semaglutide | Diabetes Mellitus, Type 2 | 218 | 2020-11-24actual | — | 2023-01-20 |
| STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or ObesityNCT03811574results2022-03-22Change in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Overweight, Obesity | 401 | 2020-11-20actual | — | 2022-03-22 |
| SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 DiabetesNCT04287179Change in glycosylated haemoglobin (HbA1c)Randomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled. | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 0 | 2020-11-16 | — | 2022-02-03 |
| To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanNCT02207218observationalFrequency of Adverse Events (AEs) | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 40 | 2020-11-10actual | — | 2021-11-15 |
| Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeNCT02527200results2022-02-03Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 WeeksRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: liraglutide, placebo | Metabolism and Nutrition Disorder, Obesity | 56 | 2020-11-04actual | — | 2023-07-06 |
| A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical RoutineNCT03888157observationalChange in glycated haemoglobin A1c (HbA1c) (percentage) | — | Completed | Drug: Liraglutide | Diabetes Mellitus, Type 2 | 839 | 2020-10-21actual | — | 2021-07-14 |
| A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection PensNCT04238962AUC0-last,sema,2mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 2 mg administration following a 6-week dose escalation periodRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide (administered by DV3396 pen-injector), Semaglutide (administered by PDS290 pen-injector) | Overweight, Obesity | 111 | 2020-10-20actual | — | 2020-11-20 |
| A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 DiabetesNCT04262661Part 1: Number of treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0472-0147, insulin glargine, Placebo (NNC0472-0147) | Healthy Volunteers, Diabetes Mellitus, Type 2 | 36 | 2020-09-25actual | — | 2022-09-28 |
| Injection Site Pain Comparison of Excipient SolutionsNCT04482725Intensity of injection site painRandomized · Quadruple-masked · Other | Phase 1 | Completed | Other: Trial product 1, Trial product 2, Trial product 3, Trial product 4, Trial product 5, Trial product 6, Trial product 7, Trial product 8, Trial product 9, Trial product 10, Trial product 10, Trial product 12 | Obesity | 108 | 2020-09-24actual | — | 2021-10-19 |
| A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityNCT04187300AUC0-168h,2.4mg,SS, Area under the semaglutide concentration time curveRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide | Overweight, Obesity | 68 | 2020-09-23actual | — | 2021-11-11 |
| A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 DiabetesNCT03989232results2021-10-22Change in HbA1cRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Diabetes Mellitus, Type 2 | 961 | 2020-09-18actual | — | 2023-02-13 |
| A Study to Look at How Safe NNC0268-0965 is in People With Type 2 DiabetesNCT04136067Number of treatment-emergent adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0268-0965, insulin glargine | Diabetes Mellitus, Type 2 | 36 | 2020-08-23actual | — | 2022-09-08 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)NCT03876015observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 215 | 2020-08-12actual | — | 2021-01-19 |
| A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a WeekNCT03723772AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec, IGlar U100 | Diabetes Mellitus, Type 1 | 66 | 2020-06-26actual | — | 2025-03-11 |
| Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 InhibitionNCT03926117results2023-08-09Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) LevelsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Ziltivekimab | Chronic Kidney Diseases, Inflammation | 264 | 2020-06-26actual | — | 2025-12-31 |
| A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseNCT03600480Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0174-0833, Semaglutide, Placebo (NNC0174-0833) | Obesity, Overweight | 96 | 2020-06-12actual | — | 2021-11-17 |
| A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of SemaglutideNCT04228354Area under the semaglutide plasma concentration curve from 0 to tzRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide | Healthy Volunteers, Overweight, Obesity | 28 | 2020-06-01actual | — | 2022-01-10 |
| A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection PensNCT04152915AUC0-last,sema,1mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation periodRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Semaglutide | Healthy Volunteers, Diabetes Mellitus, Type 2 | 68 | 2020-05-25actual | — | 2021-11-10 |
| Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With ObesityNCT03799198results2021-06-18Change in Body WeightRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Other: Weight Management Program (WMP) · Drug: Medication for chronic weight management (Rx) | Obesity | 200 | 2020-05-22actual | — | 2022-11-14 |
| A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in KoreaNCT03416855observationalNumber of Adverse events (AEs) at week 13 | — | Completed | Drug: Insulin degludec /insulin aspart | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 768 | 2020-05-19actual | — | 2021-11-10 |
| A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol LevelsNCT04058834Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0385-0434, Placebo (NNC0385-0434) | Healthy Volunteers, Hypercholesterolaemia | 39 | 2020-04-23actual | — | 2021-12-30 |
| STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548935results2021-08-11Change in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Metabolism and Nutrition Disorder, Overweight or Obesity | 1,961 | 2020-03-30actual | — | 2021-11-19 |
| Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or ObesityNCT03552757results2021-08-11Change in Body Weight (%) - Semaglutide 2.4 mg Versus PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide) | Obesity, Overweight | 1,210 | 2020-03-24actual | — | 2021-11-09 |
| A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the LiverNCT03357380Change in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide, Placebo | Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease | 67 | 2020-03-20actual | — | 2021-11-22 |
| Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle ProgramNCT03611582results2021-07-09Change in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo (semaglutide) | Overweight, Obesity | 611 | 2020-03-18actual | — | 2021-11-11 |
| Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become PregnantNCT04074174AUC0-24h,EE,SS area under the ethinylestradiol concentration-time curve during a dosing interval (0-24 hours) at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC0174-0833, Oral contraceptive (OC) tablets, Acetaminophen | Overweight, Obesity | 31 | 2020-03-06actual | — | 2022-01-10 |
| Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047results2023-07-18Change in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg) | Overweight, Obesity | 706 | 2020-03-02actual | — | 2024-07-05 |
| Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548987results2021-03-15Change From Randomisation to Week 68 in Body Weight (%)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Semaglutide, Placebo | Metabolism and Nutrition Disorder, Obesity | 902 | 2020-02-22actual | — | 2022-01-19 |
| Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.NCT02970942results2021-04-21Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide, Placebo | Hepatobiliary Disorders, Non-alcoholic Steatohepatitis | 320 | 2020-02-13actual | — | 2021-11-16 |
| Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide scNCT04189848results2021-02-17Intensity of Injection Site PainRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Semaglutide, Dulaglutide | Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity | 104 | 2020-01-29actual | — | 2022-11-07 |
| Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ANCT02035384observationalIncidence rate of FVIII inhibitors (at least 0.6 Bethesda Units (BU) for central laboratory analyses, or above the specific local laboratory reference range) represented as the percentage of patients developing inhibitors | — | Completed | Drug: turoctocog alfa | Congenital Bleeding Disorder, Haemophilia A | 69 | 2020-01-15actual | — | 2020-04-27 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)NCT03648281observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 333 | 2020-01-10actual | — | 2021-11-15 |
| A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and ObesityNCT04143945results2021-01-20Intensity of Injection Site PainRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen) | Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity | 104 | 2020-01-04actual | — | 2021-01-20 |
| Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or ObesityNCT03308721Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC9204-1177 A 1.0 mg/mL, PLACEBO | Metabolism and Nutrition Disorder, Obesity | 99 | 2020-01-03actual | — | 2021-12-23 |
| Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy PeopleNCT04059367Area under the plasma concentration-time curve extrapolated to infinity of the caffeineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NNC9204-1177, Cocktail of 5 already approved drugs | Healthy Volunteers, Overweight, Obesity | 45 | 2020-01-02actual | — | 2020-01-22 |
| A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO StudyNCT03687827results2021-01-12Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Insulin degludec, Insulin glargine | Diabetes Mellitus, Type 2 | 498 | 2019-12-20actual | — | 2021-01-12 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical PracticeNCT03457012observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 462 | 2019-12-19actual | — | 2021-09-08 |
| A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin GlargineNCT03922750results2021-01-08Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Insulin icodec, Insulin glargine U100 | Diabetes Mellitus, Type 2 | 154 | 2019-12-19actual | — | 2022-01-18 |
| A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)NCT03631186observationalChange in Glycated Haemoglobin A1c (HbA1c) | — | Completed | Drug: Semaglutide | Diabetes Mellitus, Type 2 | 215 | 2019-12-18actual | — | 2021-07-28 |
| A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.NCT03751657results2021-02-01Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine) | Diabetes Mellitus, Type 2 | 247 | 2019-12-16actual | — | 2021-04-02 |
| A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 DiabetesNCT03965013Number of treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0268-0965, Placebo, insulin glargine | Diabetes Mellitus, Type 1, Healthy Volunteers | 78 | 2019-12-14actual | — | 2021-01-14 |
| A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT03951805results2021-01-08Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Insulin icodec, Insulin Glargine | Diabetes Mellitus, Type 2 | 205 | 2019-12-12actual | — | 2021-04-05 |
| A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a WeekNCT03766854AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: insulin icodec, Insulin glargine U100 | Diabetes Mellitus, Type 1 | 24 | 2019-12-09actual | — | 2021-03-08 |
| A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With ObesityNCT03842202AUC0-5h,para: the area under the paracetamol concentration-time curve from 0 to 5 hours at steady stateRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Semaglutide, Placebo | Overweight, Obesity | 72 | 2019-11-04actual | — | 2020-12-24 |
| RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in JapanNCT03745157observationalChange in local laboratory measured glycosylated haemoglobin (HbA1c) | — | Completed | Drug: Insulin Degludec/Insulin Aspart | Diabetes Mellitus, Type 2 | 246 | 2019-10-29actual | — | 2019-12-09 |
| A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in PortugalNCT03797885observationalProportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis | — | Completed | Other: No treatment given | Diabetes Mellitus, Type 2 | 730 | 2019-10-15actual | — | 2020-11-20 |
| A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With HemophiliaNCT03660774observationalCognition composite score according to the BAYLEY-III instrument | — | Completed | Other: No treatment given | Haemophilia A, Haemophilia B | 563 | 2019-10-11actual | — | 2019-11-22 |
| A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or TogetherNCT03789578AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0148-0287sema, Semaglutide, NNC0148-0287 | Diabetes Mellitus, Type 2 | 30 | 2019-10-10actual | — | 2024-11-12 |
| An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy RegistryNCT01892319observationalProportion of pregnancies (Levemir® treatment), compared to pregnancies (other basal insulin treatment regimens), resulting in none of the following events: Major congenital malformations, Perinatal death, Neonatal death | — | Completed | Drug: insulin detemir, other injectable antidiabetic treatment regimens | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 2,446 | 2019-09-30actual | — | 2019-11-19 |
| An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 DiabetesNCT03811288observationalParticipants with a history of established cardiovascular disease (CVD) | — | Completed | Other: No treatment given | Diabetes Mellitus, Type 2 | 7,548 | 2019-09-30actual | — | 2020-06-09 |
| A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney ProblemsNCT03723785AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Insulin icodec | Diabetes Mellitus, Type 2 | 58 | 2019-09-06actual | — | 2024-07-12 |
| Research Study of a New Medicine (NNC9204-1706) in People With Overweight or ObesityNCT03661879Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC9204-1706, Placebo (NNC9204-1706) | Metabolism and Nutrition Disorder, Obesity | 60 | 2019-09-05actual | — | 2019-10-18 |
| Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® DeviceNCT03450863observationalChange in Glycated Haemoglobin (HbA1c) | — | Completed | Drug: Fast-acting insulin aspart | Diabetes, Diabetes Mellitus, Type 1 Diabetes | 320 | 2019-09-04actual | — | 2020-03-18 |
| A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or ObesityNCT04012255AUC0-168h,2.4mg,SS: Area under the semaglutide concentration time curve following the last administration of semaglutide s.c. 2.4 mgRandomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. | Drug: Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen) | Overweight, Obesity | 29 | 2019-08-30actual | — | 2019-10-23 |
| A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or ObeseNCT03707990Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0165-1875, Placebo (NNC0165-1875), Semaglutide | Obesity and Overweight | 88 | 2019-08-13actual | — | 2019-09-06 |
| Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesNCT02730377results2020-07-07Time to Inadequate Glycaemic ControlRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones | Diabetes, Diabetes Mellitus, Type 2 | 1,991 | 2019-08-05actual | — | 2020-07-07 |
| A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and ObesityNCT04007107results2020-08-04Intensity of Injection Site PainRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen) | Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity | 103 | 2019-07-28actual | — | 2020-08-04 |
| A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or ObeseNCT03574584Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0165-1562, Semaglutide, Placebo (NNC0165-1562) | Metabolism and Nutrition Disorders, Overweight or Obesity | 37 | 2019-07-27actual | — | 2021-07-02 |
| A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy SubjectsNCT03905850Area under the somapacitan serum concentration time curve from time 0 to the time of the last quantifiable concentration after dosingRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: somapacitan | Healthy Volunteers, Growth Hormone Deficiency | 33 | 2019-07-15actual | — | 2019-08-06 |
| Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational StudyNCT01862367observationalAdverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with rFXIII,comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of effect collected | — | Completed | Drug: catridecacog | Congenital Bleeding Disorder, Congenital FXIII Deficiency | 30 | 2019-06-26actual | — | 2019-07-09 |
| A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in KoreaNCT02779413observationalNumber of Adverse Events (AE) | — | Completed | Drug: insulin degludec | Diabetes | 3,303 | 2019-06-24actual | — | 2020-04-21 |
| Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 TrialNCT03588741results2020-07-07Number of Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The trial was terminated as the participant withdrew from the trial. | Drug: Turoctocog alfa | Haemophilia A | 1 | 2019-06-19actual | — | 2020-07-07 |
| A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)NCT03172494results2020-07-07Change in HbA1cRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin degludec/liraglutide, Insulin degludec, Liraglutide | Diabetes, Diabetes Mellitus, Type 2 | 720 | 2019-06-14actual | — | 2022-12-14 |
| A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and GlargineNCT03960814observationalAge at all cause death or censoring | — | Completed | Drug: Insulin detemir | Diabetes Mellitus, Type 2 | 12,847 | 2019-06-07actual | — | 2019-07-18 |
| A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or ObesityNCT03479892Number of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0194-0499, Placebo | Metabolism and Nutrition Disorder, Obesity | 57 | 2019-06-04actual | — | 2019-06-26 |
| A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityNCT03787225AUC0-∞,AM833: the area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after single doseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: NNC0174-0833, Placebo (NNC0174-0833) | Obesity, Overweight | 66 | 2019-06-04actual | — | 2019-06-24 |
| An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 DiabetesNCT03786406observationalDiagnosed with cerebrovascular disease: Ischaemic stroke, haemorrhagic stroke, stroke (unspecified) and/or transient ischaemic attack | — | Completed | Other: No treatment given | Diabetes Mellitus, Type 2 | 2,275 | 2019-05-31actual | — | 2023-06-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19